Treatment of asthma by blocking IL-13 and TSLP
By developing a compound that simultaneously blocks TSLP and IL-13, the problem of poor efficacy of existing asthma treatments has been solved, resulting in a significant reduction in FeNO levels and eosinophil counts, and improving lung function in asthma patients.
Patent Information
- Application Number
- CN202480020769.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-06
- Filing Date
- 2024-03-25
- Publication Date
- 2025-11-14
AI Technical Summary
Existing asthma treatments are not effective for some patients, especially those with low or high eosinophilic asthma, and existing dual-targeted therapies are inconvenient and costly to use in combination.
To develop a compound that can simultaneously block TSLP and IL-13, thereby reducing exhaled nitric oxide (FeNO) levels and eosinophil count, and improving airway inflammation and lung function.
It significantly reduces FeNO levels by at least 18 ppb, eosinophil count by at least 30%, and increases FEV1, alleviating airway inflammation and preventing loss of lung function.
Smart Images

Figure BDA0005606647800001051 
Figure BDA0005606647800001061 
Figure BDA0005606647800001071
Abstract
Description
Technical Field
[0001] This invention relates to the treatment of asthma by administration of compounds that bind to IL-13 and TSLP. Blocking these two cytokines has shown one or more significant effects, such as a reduction of at least 18 ppb in exhaled nitric oxide (FeNO) levels compared to a control (e.g., placebo), and a reduction of at least 30% in the eosinophil count in the blood compared to a control (e.g., placebo). Treatment may also reduce airway inflammation and decrease obstruction of small airways. Background Technology
[0002] While essential for host defense, uncontrolled immune responses can lead to a range of inflammatory diseases, such as asthma, atopic dermatitis, and rheumatoid arthritis. A cascade of immune responses mediated by the innate and adaptive groups of the immune system (e.g., antigen recognition, antigen processing, antigen presentation, cytokine production, antibody production, target cell killing) drives the initiation and spread of a range of immune diseases. Inflammatory diseases are often chronic and can even be life-threatening. Allergic and atopic diseases (such as asthma) are typically driven primarily by type 2 immune responses and are characterized by prominent type 2 immune features, such as high IgE production and eosinophilia.
[0003] Thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13) are targets of soluble cytokines produced by stromal and / or immune cells (Ziegler and Artis, Nat Rev Immunol (2010) 11:289; Gieseck III et al., Nat Rev Immunol (2018) 18:62). Human TSLP and IL-13 drive distinct, overlapping, and synergistic aspects of immunity and autoimmunity (e.g., type 2 inflammation).
[0004] TSLP signaling is initiated via a heterodimeric receptor complex consisting of the thymic stromal lymphopoietin receptor (TSLPR) and the IL-7Rα chain (IL-7Rα). Similarly, IL-13 signaling is initiated via binding to a heterodimeric receptor complex consisting of the αIL-4 receptor (IL-4Rα) and the α-interleukin-13 receptor (IL-13R1α). The high affinity of IL-13 for IL-13R1 leads to the formation of its complex, which further increases the likelihood of heterodimer formation with IL-4Rα.
[0005] TSLP drives the maturation of dendritic cells, the development and proliferation of mast cells, and the initiation of other immune cells, such as basophils and innate lymphoid cells (ILC2). Similarly, IL-13 influences a range of immunopathologies, including epithelial barrier disruption, mucus production on muco-epithelial surfaces, airway remodeling, and the induction of eosinophil recruitment of chemokines, such as eosinophil chemokine. These mechanisms are important for the initiation and spread of type 2 inflammatory responses and for the development of a range of immunopathologies in diseases such as atopic dermatitis and asthma.
[0006] Not all patients with moderate / severe asthma respond adequately to currently available standard of care (including biologics such as the anti-IL4Rα monoclonal antibody Dupixent (dupilumab; marketed), anti-IL5 (marketed), and the anti-IgE monoclonal antibody Xolair (omalizumab; marketed)). There are specific unmet needs in asthma patients with a low eosinophilic phenotype. While antagonistic monoclonal antibodies against TSLP (tezepelumab; marketed) and IL-13 (lebrikizumab) exist, there are no marketed compounds targeting both TSLP and IL-13. Dual targeting of TSLP and IL-13 with a single compound has the potential to confer efficacy in both low and high eosinophilic asthma, potentially in subgroups within these indications where monospecific therapy may not be fully effective.
[0007] Targeting multiple disease factors can be achieved, for example, through the co-administration or combination of two separate biologics (e.g., antibodies that bind to different therapeutic targets). However, from both a practical and commercial perspective, the co-administration or combination of separate biologics can be challenging. For example, two injections of a single product present a more inconvenient and painful treatment regimen for patients, which can negatively impact adherence. Regarding a single injection of two separate products, providing formulations that allow for acceptable viscosity and suitable stability of both products at the desired concentrations may be difficult or impossible. Furthermore, co-administration and co-formulation require the production of two separate drugs, which can increase overall costs. Bispecific antibodies capable of binding to two different antigens have been suggested as a strategy to address such limitations associated with the co-administration or combination of separate biologics (such as antibodies).
[0008] These factors have hindered the development of multispecific asthma therapies. Therefore, there is a significant need for alternative asthma treatments that target multiple pathological pathways. This invention addresses this need by providing compounds that combine both TSLP and IL-13 for use in the treatment of lung diseases (e.g., asthma). This invention demonstrates for the first time that simultaneously targeting TSLP and IL-13 is highly effective in asthma patients. Specifically, this invention shows that treatment with compounds that block TSLP and IL-13 results in improvements in specific clinical parameters (such as FeNO levels) to a greater extent than with existing asthma medications. Summary of the Invention
[0009] This invention demonstrates for the first time the potent effect of simultaneously blocking TSLP and IL-13 in human subjects with lung diseases such as asthma. Specifically, this effect achieved a reduction of at least 18 ppb in FeNO levels compared to baseline FeNO levels or placebo, and / or a reduction of at least 30% in eosinophil count compared to baseline eosinophil count or placebo, and / or an increase of at least 0.07 L in FEV1 compared to baseline forced expiratory volume in one second (FEV1) or placebo. This invention demonstrates that simultaneously blocking TSLP and IL-13 reduces airway inflammation and improves lung function in human subjects.
[0010] On the other hand, the present invention relates to a preventative aspect. Because the present invention provides a way to reduce FeNO levels to a greater extent than known treatments, this opens up the possibility of prophylactic administration to treat subjects with elevated FeNO levels, thereby preventing lung function loss even before it occurs. This prophylactic administration can be for patients with asthma and subjects at risk of developing asthma, as well as patients with other lung diseases and subjects at risk of developing other lung diseases. Therefore, the present invention relates to compounds for use in reducing FeNO levels in subjects, wherein the reduction of FeNO levels prevents lung function loss.
[0011] The present invention provides the following exemplary embodiments:
[0012] [1] A compound combining IL-13 and TSLP, the use of said compound in treating a lung disease in a subject, wherein said treatment reduced the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
[0013] [2] The compound for the purpose according to embodiment [1], wherein the treatment reduces the level of FeNO by at least 20 ppb, at least 30 ppb or at least 40 ppb compared to a control.
[0014] [3] The compound for the purpose according to any one of the foregoing embodiments, wherein the lung disease is asthma.
[0015] [4] The compound for the purpose according to embodiment [3], wherein the asthma is hypereosinophilic asthma.
[0016] [5] The compound for the purpose according to embodiment [3], wherein the asthma is hypoeosinophilic asthma.
[0017] [6] The compound for the purpose according to any one of the foregoing embodiments, wherein the control is a baseline or wherein the control is a placebo, optionally wherein the baseline means the individual baseline of the subject.
[0018] [7] The compound for the purpose according to any one of the foregoing embodiments, wherein the reduction in FeNO level occurs within 4 weeks after application of the compound, wherein optionally the reduction in FeNO level occurs within 2 weeks after application of the compound, wherein optionally the reduction in FeNO level occurs within 1 week after application of the compound.
[0019] [8] The compound for the purpose according to any one of the foregoing embodiments, wherein the compound that binds IL-13 and TSLP is a polypeptide, such as an antibody or antibody fragment.
[0020] [9] The compound for the purpose according to embodiment [8], wherein the polypeptide comprises or consists of at least four ISVDs, wherein two ISVDs specifically bind to IL-13 and two ISVDs specifically bind to TSLP, wherein each of the at least four ISVDs comprises three complementarity-determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptide linkers, and wherein:
[0021] The first ISVD includes:
[0022] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:7, CDR2 is the amino acid sequence of SEQ ID NO:12, and CDR3 is the amino acid sequence of SEQ ID NO:17;
[0023] The second ISVD includes:
[0024] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:8, CDR2 is the amino acid sequence of SEQ ID NO:13, and CDR3 is the amino acid sequence of SEQ ID NO:18;
[0025] The third ISVD includes:
[0026] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:9, CDR2 is the amino acid sequence of SEQ ID NO:14, and CDR3 is the amino acid sequence of SEQ ID NO:19.
[0027] The fourth ISVD includes:
[0028] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:11, CDR2 is the amino acid sequence of SEQ ID NO:16, and CDR3 is the amino acid sequence of SEQ ID NO:21.
[0029]
[10] The compound for the purpose according to any one of embodiments 8 and 9, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1 or is composed of... The amino acid sequence composition of SEQ ID NO:1.
[0030]
[11] The compound for the purpose according to any one of the foregoing embodiments, wherein the subject's baseline FeNO level is at least 50 ppb and the eosinophil count is greater than or equal to 0.3 × 10⁻⁶. 9 Cells / L
[0031]
[12] A compound combining IL-13 and TSLP, used in treating a subject with a lung disease, wherein the treatment reduced the eosinophil count in the blood by at least 30% compared to a control.
[0032]
[13] The compound for the purpose according to embodiment
[12] , wherein the reduction in eosinophil count occurs within 4 weeks after application of the compound, wherein optionally the reduction in eosinophil count occurs within 2 weeks after application of the compound, wherein optionally the reduction in eosinophil count occurs within 1 week after application of the compound.
[0033]
[14] A compound combining IL-13 and TSLP, used in treating a subject’s lung disease, wherein the treatment reduces airway inflammation.
[0034]
[15] The compound for the purpose according to embodiment
[14] , wherein the reduction of airway inflammation is characterized by a reduction of FeNO by at least 18 ppb, a reduction of eosinophil count by at least 30%, and / or an increase of forced expiratory volume in one second (FEV1) by at least 0.07 L compared to a control.
[0035]
[16] The compound for the purpose according to embodiment
[15] , wherein the reduction of airway inflammation occurs within 4 weeks after administration of the compound, wherein optionally the reduction of airway inflammation occurs within 2 weeks after administration of the compound, and wherein optionally the reduction of airway inflammation occurs within 1 week after administration of the compound.
[0036] In another aspect, the present invention provides the following exemplary embodiments:
[0037]
[17] A compound that combines TSLP and / or IL-13, the use of said compound in reducing FeNO levels in subjects, wherein said reduction in FeNO levels prevents loss of lung function.
[0038]
[18] The compound for the purpose according to embodiment
[17] , wherein the reduction in FeNO level is a reduction of at least 18 ppb.
[0039]
[19] The compound for the said use according to any one of embodiments
[18] and
[19] , wherein the reduction in FeNO level is a reduction to a level below 25 ppb.
[0040]
[20] The compound for the use according to any one of the embodiments
[17] ,
[18] and
[19] , wherein the baseline FeNO level of the subject is at least 50 ppb, at least 35 ppb or at least 25 ppb.
[0041]
[21] The compound for the purpose according to any one of embodiments
[17] ,
[18] ,
[19] and
[20] , wherein the subject's baseline FeNO level is at least 50 ppb and the eosinophil count is greater than or equal to 0.3 × 10⁻⁶. 9 Cells / L
[0042]
[22] A compound for the purpose according to any one of embodiments
[17] ,
[18] ,
[19] ,
[20] and
[21] , wherein the compound is combined with TSLP and IL-13.
[0043]
[23] The compound for the use according to any one of the embodiments
[17] ,
[18] ,
[19] ,
[20] ,
[21] and
[22] , wherein the loss of lung function is associated with asthma. Attached Figure Description
[0044] Figure 1 : Timeline of the clinical trial for Example 1 (PDY16622). The timeline indicates the treatments / measurements performed at designated time points (“D” stands for “day”) in the clinical trial.
[0045] Figure 2 FeNO measurement results from the clinical trial of Example 1 (PDY16622). The changes in exhaled nitric oxide levels (in parts per billion, ppb) from baseline are shown in the SAR443765 group (dashed line) and the placebo group (solid line).
[0046] Figure 3 FeNO measurements from the clinical trial of Example 1 (PDY16622) based on the high / low eosinophil subgroup analysis are shown. The changes in exhaled nitric oxide levels (in parts per billion, ppb) from baseline are shown for the high eosinophil SAR443765 group (lower dashed line, dark gray), the low eosinophil SAR443765 group (lower solid line, dark gray), the high eosinophil placebo group (upper dashed line, light gray), and the low eosinophil placebo group (upper solid line, light gray).
[0047] Figure 4 Eosinophil counts in the clinical trial of Example 1 (PDY16622). Median changes in eosinophil counts from baseline are shown in the SAR443765 group (right) and the placebo group (left) at D29 (4 weeks).
[0048] Figure 5 On D29, the eosinophil counts in the clinical trial of Example 1 (PDY16622, right bar) compared to the following three other biologics: lerechizumab (left bar), terzeglundumab (second bar from left), and dupilumab (second bar from right).
[0049] Figure 6 Example 1 (PDY16622): FEV1 measurements from the clinical trial. Changes in FEV1 (in liters, compared to baseline) in the SAR443765 group (dashed line) and the placebo group (solid line) are shown. All measurements are included.
[0050] Figure 7 Example 1 (PDY16622): FEV1 measurements from the clinical trial. Changes in FEV1 (in liters, compared to baseline) in the SAR443765 group (dashed line) and the placebo group (solid line) are shown. Only measurements that met all quality criteria are included.
[0051] Figure 8 FEV1 measurement results from the clinical trial of Example 1 (PDY16622). As shown... Figure 7The changes in FEV1 (in liters, compared to baseline) are shown in the figure. Based on the percentage of predicted FEV1 (ppFEV1) from baseline, the SAR443765 group and the placebo group were each divided into two subgroups. The subgroups were: SAR443765, baseline ppFEV1 ≥ 80% (dark gray solid line); SAR443765, baseline ppFEV1 < 80% (dark gray dashed line); placebo, baseline ppFEV1 ≥ 80% (light gray solid line); placebo, baseline ppFEV1 < 80% (light gray dashed line).
[0052] Figure 9 Example 1 (PDY16622) clinical trial results of forced expiratory flow rate 25%–75% (FEF25–75). The changes in FEF25–75 (in liters / s, compared to baseline) are shown. The top graph shows the changes in FEF25–75 for the SAR443765 group (dashed line) and the placebo group (solid line). In the bottom graph, the SAR443765 group and the placebo group are each divided into two subgroups based on baseline FEV1 as a percentage of predicted value (ppFEV1). Subgroups are: SAR443765, baseline ppFEV1 ≥ 80% (dark gray solid line); SAR443765, baseline ppFEV1 < 80% (dark gray dashed line); placebo, baseline ppFEV1 ≥ 80% (light gray solid line); placebo, baseline ppFEV1 < 80% (light gray dashed line).
[0053] Figure 10 Example 1 (PDY16622) clinical trial results show the measurement of the difference in respiratory resistance at 5 Hz and 20 Hz (R5-20). The variation in the difference between respiratory resistance at 5 Hz and 20 Hz (in cmH2O*s / L, compared to baseline) is shown. The top graph shows the variation in R5-20 for the SAR443765 group (dashed line) and the placebo group (solid line). In the bottom graph, the SAR443765 group and the placebo group are each divided into two subgroups based on the baseline percentage of predicted FEV1 (ppFEV1). Subgroups are: SAR443765, baseline ppFEV1 ≥ 80% (dark gray solid line); SAR443765, baseline ppFEV1 < 80% (dark gray dashed line); placebo, baseline ppFEV1 ≥ 80% (light gray solid line); placebo, baseline ppFEV1 < 80% (light gray dashed line).
[0054] Figure 11The results of the resistivity area (AX) measurement in the clinical trial of Example 1 (PDY16622) are shown. The change in resistivity area (in cmH2O / L) compared to baseline is illustrated. The top graph shows the change in resistivity area in the SAR443765 group (dashed line) and the placebo group (solid line). In the bottom graph, the SAR443765 group and the placebo group are each divided into two subgroups based on the baseline percentage of predicted FEV1 (ppFEV1). The subgroups are: SAR443765, baseline ppFEV1 ≥ 80% (dark gray solid line); SAR443765, baseline ppFEV1 < 80% (dark gray dashed line); placebo, baseline ppFEV1 ≥ 80% (light gray solid line); placebo, baseline ppFEV1 < 80% (light gray dashed line).
[0055] Figure 12 Additional biomarker measurements from the clinical trial of Example 1 (PDY16622). The changes from baseline are shown for serum IL-5 levels (top left); plasma CCL26 (eosinophil chemokine-3) levels (top right); serum IgE levels (bottom left); and serum TARC (CCL17) levels (bottom right). Each graph shows results for placebo (left) and SAR443765 (right).
[0056] Figure 13 Changes in cell types in nasal brush samples from the clinical trial of Example 1 (PDY16622). Changes are shown between samples from D1 (baseline, before administration of SAR443765 or placebo) and D29. The change in the proportion of each cell type on the x-axis (expressed as log2 of the fold change (FC)) is plotted against the p-value of that change on the y-axis (expressed as -log10 of the p-value).
[0057] Figure 14 Example 1 (PDY16622): Changes in cell types in peripheral blood leukocyte (PBL) samples from the clinical trial. Changes are shown between samples from D1 (baseline, before SAR443765 or placebo administration) and D29. The change in the proportion of each cell type on the x-axis (expressed as log2 of the fold change (FC)) is plotted against the p-value of that change on the y-axis (expressed as -log10 of the p-value).
[0058] Figure 15The correlation between changes in NK cell proportion (in PBL samples) and changes in FeNO levels in the clinical trial of Example 1 (PDY16622) is shown. Changes between samples / measurements from D1 (baseline, before SAR443765 or placebo administration) and D29 are illustrated. The change in FeNO on the x-axis is plotted against the change in the cell type proportion of NK cells on the y-axis (D29-D1) (expressed as log10 of fold change (FC)).
[0059] Figure 16 CCL26 expression in nasal brush samples from the clinical trial of Example 1 (PDY16622) at D1 and D29. In the SAR443765 group, there were significant differences in CCL26 expression between D1 and D29 for cell types: epithelial basal cells, epithelial multiciliated cells, and epithelial secretory cells.
[0060] Figure 17 Example 1 (PDY16622): HBB expression in CD8 T-effect memory (em) cells from PBL samples of the clinical trial. The fold change in HBB gene expression relative to the p-value is shown (D29 vs. D1). In the SAR443765 group (left), the downregulation of HBB expression was stronger than in the placebo group (right). Detailed Implementation
[0061] In a first aspect, the present invention relates to a compound that blocks TSLP and IL-13 for use in treating a lung disease in a subject (e.g., in treating asthma). This treatment is characterized by improvements in certain biomarkers, particularly a reduction in FeNO levels and a reduction in eosinophil count.
[0062] On the other hand, the present invention relates to compounds for use in reducing FeNO levels in subjects, wherein the reduction in FeNO levels prevents loss of lung function. This loss of lung function may be associated with asthma or another lung disease.
[0063] 5.1 Definition
[0064] Unless otherwise stated below, all terms used in this application (including the specification and the claims) have the meanings that are usually given to them in their respective scientific fields.
[0065] As used in this specification and the appended claims, the indefinite articles “a” and “an” and the definite article “the” include both plural and singular indicators, unless the context clearly indicates otherwise.
[0066] In this application, all indications of time spans designate the day of drug administration as day 1 (“D1”). This means that the day following drug administration is designated as day 2 (“D2”), such that, for example, a measurement occurring 24 hours after drug administration is on D2, and a measurement occurring 72 hours after drug administration is on D4. This also means that a one-week time span ends on D8, a two-week time span ends on D15, a three-week time span ends on D22, a four-week time span ends on D29, an eight-week time span ends on D57, and a ten-week time span ends on D71. In this disclosure, “day” is generally abbreviated as “D”. The terms “day” and “D” are used interchangeably in this disclosure.
[0067] Lung disease is a disease of the lungs. An example of lung disease is asthma.
[0068] Inflammatory diseases are characterized by auto-inflammation. Inflammatory diseases can occur in the lungs. An example of such a lung inflammatory disease is asthma.
[0069] Asthma is a lung disease characterized by chronic airway inflammation. Asthma involves airway obstruction and triggered bronchospasm. Symptoms typically include wheezing, coughing, chest tightness, and shortness of breath. Asthma includes allergic, non-allergic, Th2 hyperasthmatic, Th2 hypoasthmatic, hypereosinophilic, and hypoeosinophilic asthma.
[0070] As used in this article, hypereosinophilic asthma is asthma in which the patient shows an eosinophil count greater than or equal to 0.3 × 10⁻⁶. 9 Cells / L. An exemplary eosinophil count range in hypereosinophilic asthma is 0.3 × 10⁻⁶ cells / L. 9 Up to 0.5×10 9 Cells / L
[0071] As used in this article, hypoeosinophilic asthma is asthma in which patients show an eosinophil count of less than 0.3 x 10^9. 9 Cells / L. In hypoeosinophilic asthma, an exemplary eosinophil count range is 0 to less than 0.3 × 10⁻⁶ cells / L. 9 Cells / L
[0072] Airway inflammation is inflammation of the respiratory tract. It can be assessed directly, for example, by induced sputum analysis, bronchoscopy, bronchial biopsy, or exhaled volatile markers (such as FeNO); or indirectly, for example, by an increased eosinophil count in the blood. Airway inflammation is characterized by elevated FeNO levels, elevated blood eosinophil count, and decreased lung function (e.g., decreased FEV1).
[0073] Type 2 inflammation is an immune response characterized by the initiation of type 2 T helper cells and / or type 2 innate lymphoid cells. The immune response of type 2 inflammation is characterized by the release of alarming factors (IL-23, IL-33, TSLP), which leads to the initiation of type 2 T helper cells and / or type 2 innate lymphoid cells. These cells secrete IL-4, IL-5, and IL-13, which promotes isoform conversion of B cells to IgE and eosinophil recruitment. Type 2 inflammation can be used for the body's defense against worms, but it is also involved in a variety of autoinflammatory diseases. Airway inflammation in asthma patients is often type 2 inflammation.
[0074] Exhaled nitric oxide (FeNO) is the fraction of nitric oxide (NO) in exhaled air. It is measured in parts per billion (ppb). Elevated FeNO levels are a marker of airway inflammation. When this application refers to "a reduction in FeNO levels compared to placebo," it refers to the average of the individual changes in FeNO levels from baseline in the compound group (in ppb) and the placebo group (in ppb) at a given time point. The difference between these two values (in ppb) is "the reduction in FeNO levels compared to placebo."
[0075] As used in this article, managing elevated FeNO levels means administering treatments that reduce elevated FeNO levels, which can alleviate airway inflammation and / or prevent the worsening of airway inflammation.
[0076] As used in this article, managing airway inflammation means administering treatments that reduce airway inflammation, thereby alleviating symptoms associated with airway inflammation and / or preventing the worsening of symptoms associated with airway inflammation.
[0077] As used herein, eosinophil count is the number of eosinophils. In the treatment according to the invention, the eosinophil count in whole blood is measured. Methods for measuring the eosinophil count are known in the art, such as flow cytometry or microscopic counting after H&E staining. The eosinophil count is measured in cells / L. When this application refers to “a reduction in eosinophil count compared to placebo,” this means, at some point after the start of treatment, measuring the change in eosinophil count in the compound group compared to baseline (in cells / L or %) and the change in eosinophil count in the placebo group compared to baseline (in cells / L or %). The difference between these two values (in cells / L or %) is “the reduction in eosinophil count compared to placebo.”
[0078] Forced expiratory volume in one second (FEV1) is the volume exhaled at the end of the first second of a forced exhalation following maximal inspiration. FEV1 can be measured using a spirometer. When this application refers to "an increase in FEV1 compared to placebo," it means, at some time point after the start of treatment, measuring the change in FEV1 from baseline (in L) in the compound group and the change in FEV1 from baseline (in L) in the placebo group. The difference between these two values (in L) is "an increase in FEV1 compared to placebo."
[0079] As used herein, a placebo is a treatment or substance used for such treatment that does not contain a pharmacologically active compound. In clinical trials, a group of participants may be given a placebo to create a control group of participants who receive a pharmacologically active compound being tested. For use as an appropriate control, the treatment with a placebo is identical to the treatment being compared, except that a placebo (e.g., an inert pill, like a sugar pill) is administered instead of a pharmacologically active compound.
[0080] In this invention, changes in biomarkers (e.g., FeNO, eosinophil count) are determined compared to a “control.” A control is the subject’s “baseline,” i.e., the subject’s biomarker levels before administration of the compound of this invention; or a “placebo,” i.e., the biomarker levels after administration of a placebo instead of the compound of this invention. When determining changes in biomarker levels compared to baseline, this means calculating the difference between the baseline biomarker level and the biomarker level at a certain time point for each subject treated with the compound. This calculation can be performed on individual subjects and on a group of subjects. If performed on individual subjects, the difference is directly expressed as the change in biomarker level compared to baseline. If performed on a group of subjects, the mean or median of all differences calculated for individual subjects is expressed as the change in biomarker level compared to baseline.
[0081] When determining changes in biomarker levels compared to placebo, this means determining the change from baseline for one group of subjects treated with the compound (as explained in the previous sentence) and the same value for one group of subjects treated with placebo; the difference between these two values is expressed as the change in biomarker level compared to placebo. This means that the change in biomarker level compared to placebo is equal to "change in biomarker level compared to baseline" minus the change in biomarker level in the placebo group.
[0082] Small airways are those with a diameter equal to or less than 2 mm, as commonly defined in the literature (see, for example, McNulty and Usmani, Eur Clin Respir J, 2014 and Stockley et al., Int J Chron Obstruct Pulmon Dis. 2017; 12: 2343-2353).
[0083] Large airways refer to those airways with a diameter exceeding 2 mm.
[0084] The participants in the clinical trial of Example 1 (PDY16622) consisted of asthma patients (see Example 1 below). Therefore, the terms "participant" and "patient" are used synonymously throughout this application.
[0085] The phrases "treating the subject's disease" and "treating the disease" are used interchangeably in this text because treatment obviously occurs within the subject. The same applies to variations of this phrase; for example, "treating the subject's lung disease" and "treating the lung disease" are interchangeable.
[0086] 5.2 Therapeutic effects of the present invention
[0087] This invention provides compounds combining IL-13 and TSLP for use in treating lung diseases in subjects. These treatments are characterized by improvements in biomarkers and / or physiological characteristics, such as reduced FeNO levels, reduced eosinophil counts in the blood, increased FEV1, and / or reduced airway inflammation.
[0088] The subjects of treatment according to the present invention can be any animal, and more specifically, mammals. Among mammals, humans and non-human mammals can be distinguished. Non-human animals can be, for example, companion animals (e.g., dogs, cats), livestock (e.g., cattle, horses, sheep, goats, or pigs), or animals commonly used for research purposes and / or for antibody production (e.g., mice, rats, rabbits, cats, dogs, goats, sheep, horses, pigs, non-human primates (e.g., cynomolgus monkeys), or camelids (e.g., llamas or alpacas)). In one embodiment, the subject is a human subject.
[0089] In the context of the preventive purpose of this invention, the subject may be the same as defined in the preceding sections. In one embodiment, the subject is a human subject.
[0090] The compounds (including polypeptides and nucleic acid molecules) or compositions according to the invention can be administered to a subject via any suitable route of administration, for example, via enteral (e.g., oral or rectal) or parenteral (e.g., epidermal, sublingual, buccal, nasal, intra-articular, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous (SC), transdermal, or transmucosal). In one embodiment, the substance is administered via parenteral administration (e.g., intramuscular, subcutaneous, or intradermal). In one embodiment, subcutaneous administration is used.
[0091] An effective amount of a polypeptide, nucleic acid molecule, or a composition containing a polypeptide or nucleic acid molecule may be administered to a subject in order to provide the desired therapeutic outcome.
[0092] One or more doses may be administered. If more than one dose is administered, the doses may be given at appropriate intervals to maximize the effect of the peptide, composition, nucleic acid molecule, or carrier.
[0093] In some embodiments, the compound combining TSLP and IL-13 is administered at a dose of 400 mg. In some embodiments, the compound combining TSLP and IL-13 is administered subcutaneously (SC). In some embodiments, only a single dose of the compound combining TSLP and IL-13 is administered.
[0094] In some embodiments, the compound combining TSLP and IL-13 is administered in an amount of 400 mg, and is administered subcutaneously (SC). In some embodiments, the compound combining TSLP and IL-13 is administered in an amount of 400 mg, and only one dose of the compound combining TSLP and IL-13 is administered. In some embodiments, the compound combining TSLP and IL-13 is administered subcutaneously (SC), and only one dose of the compound combining TSLP and IL-13 is administered. In some embodiments, the compound combining TSLP and IL-13 is administered in an amount of 400 mg, subcutaneously (SC), and only one dose of the compound combining TSLP and IL-13 is administered.
[0095] 5.2.1 Reduction in FeNO levels
[0096] A reduction in FeNO levels reflects reduced airway inflammation and is therefore beneficial for patients with lung diseases (e.g., asthma). In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0097] In this invention, a reduction in FeNO levels is determined by comparison with a control. The control is the subject's "baseline," i.e., the subject's FeNO level before administration of the compound of this invention; or the "placebo," i.e., the FeNO level after administration of a placebo instead of the compound of this invention. When determining a reduction in FeNO levels compared to baseline, this means calculating the difference between the baseline FeNO level and the FeNO level at a certain time point for each subject treated with the compound. This calculation can be performed on individual subjects as well as on a group of subjects. If performed on individual subjects, the difference is directly expressed as the change in FeNO levels compared to baseline. If performed on a group of subjects, the mean or median of all differences calculated for individual subjects is expressed as the change in FeNO levels compared to baseline.
[0098] When determining a reduction in FeNO levels compared to a placebo, this means determining a reduction from baseline for a group of subjects treated with the compound (as explained in the previous sentence) and the same value for a group of subjects treated with a placebo; the difference between these two values is expressed as the reduction in FeNO levels compared to a placebo. This means that the reduction in FeNO levels compared to a placebo is equal to "the reduction in FeNO levels compared to baseline" minus the change in FeNO levels from baseline in the placebo group. In some implementations, the reduction in FeNO levels is calculated based on the mean of a group of subjects. In some implementations, the reduction in FeNO levels is calculated based on the median of a group of subjects.
[0099] In some embodiments of the invention, a reduction in FeNO levels is determined compared to a placebo. In some embodiments of the invention, a reduction in FeNO levels is determined compared to a baseline. In some embodiments of the invention, a reduction in FeNO levels is determined compared to a baseline, where baseline refers to the subject's isolated baseline. In some embodiments of the invention, the FeNO level is reduced by at least 18 ppb. In some embodiments of the invention, the FeNO level is reduced by at least 20 ppb. In some embodiments of the invention, the FeNO level is reduced by at least 25 ppb. In some embodiments of the invention, the FeNO level is reduced by at least 30 ppb. In some embodiments of the invention, the FeNO level is reduced by at least 35 ppb. In some embodiments of the invention, the FeNO level is reduced by at least 40 ppb.
[0100] Exemplary ranges for the reduction in FeNO levels are 18 ppb to 50 ppb; 18 ppb to 40 ppb; 18 ppb to 35 ppb; 18 ppb to 30 ppb; 18 ppb to 25 ppb; 18 ppb to 20 ppb; 20 ppb to 50 ppb; 20 ppb to 40 ppb; 20 ppb to 35 ppb; 20 ppb to 30 ppb; 20 ppb to 25 ppb; 25 ppb to 50 ppb; 25 ppb to 40 ppb; 25 ppb to 35 ppb; 25 ppb to 30 ppb; 25 ppb to 30 ppb; 30 ppb to 50 ppb; 30 ppb to 40 ppb; 30 ppb to 35 ppb; 35 ppb to 50 ppb; 35 ppb to 40 ppb; 40 ppb to 50 ppb.
[0101] Evaluation can be performed at different time points after application of the compound of the present invention. The reduction in FeNO levels. In some embodiments, the reduction in FeNO levels is assessed 1 week after application of the compound of the present invention. In some embodiments, the reduction in FeNO levels is assessed 2 weeks after application of the compound of the present invention. In some embodiments, the reduction in FeNO levels is assessed 3 weeks after application of the compound of the present invention. In some embodiments, the reduction in FeNO levels is assessed 4 weeks after application of the compound of the present invention. In some embodiments, the reduction in FeNO levels is assessed 8 weeks after application of the compound of the present invention.
[0102] The treatment of the present invention can be used to manage elevated FeNO levels. In some embodiments, managing FeNO levels includes reducing FeNO levels to less than 40 ppb. In some embodiments, managing FeNO levels includes reducing FeNO levels to less than 35. In some embodiments, managing FeNO levels includes reducing FeNO levels to less than 30. In some embodiments, managing FeNO levels includes reducing FeNO levels to less than 25. In some embodiments, managing FeNO levels includes reducing FeNO levels to less than 20.
[0103] The FeNO baseline level (i.e., the level before compound administration) can also be a parameter of the treatment of the present invention. In some embodiments, the treatment of the present invention is used to manage an elevated FeNO baseline level of at least 25 ppb. In some embodiments, the treatment of the present invention is used to manage an elevated FeNO baseline level of at least 30 ppb. In some embodiments, the treatment of the present invention is used to manage an elevated FeNO baseline level of at least 40 ppb. In some embodiments, the treatment of the present invention is used to manage an elevated FeNO baseline level of at least 50 ppb. In some embodiments, the treatment of the present invention is used to manage an elevated FeNO baseline level of at least 60 ppb. In some embodiments, the treatment of the present invention is used to manage an elevated FeNO baseline level of at least 70 ppb.
[0104] In some embodiments, the treatment of the present invention is used to manage an elevated baseline FeNO level of at least 50 ppb, wherein the subject also has a FeNO level greater than or equal to 0.3 × 10⁻⁶. 9 Eosinophil count per cell / L. Exemplary baseline FeNO levels range from 50 ppb to 150 ppb, and exemplary eosinophil counts range from 0.3 × 10⁻⁶ cells / L. 9 Up to 0.5×10 9 Cells / L
[0105] 5.2.2 Decrease in eosinophil count in the blood
[0106] A decrease in the eosinophil count in the blood is associated with reduced airway inflammation (especially type 2 airway inflammation) and is therefore beneficial for patients with lung diseases (e.g., asthma). In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0107] In this invention, a reduction in eosinophil count level is determined compared to a control. A control is the subject's "baseline," i.e., the subject's eosinophil count before administration of the compound of this invention; or a "placebo," i.e., the eosinophil count after administration of a placebo instead of the compound of this invention. When a reduction in eosinophil count is determined compared to baseline, this means calculating the difference between the baseline eosinophil count and the eosinophil count at a certain time point for each subject treated with the compound. This calculation can be performed on individual subjects and on a group of subjects. If performed on individual subjects, the difference is directly expressed as the change in eosinophil count compared to baseline. If performed on a group of subjects, the mean or median of all differences calculated for individual subjects is expressed as the reduction in eosinophil count compared to baseline. When a reduction in eosinophil count is determined compared to placebo, this means determining a reduction from baseline for one group of subjects treated with the compound (as explained in the previous sentence) and the same value for one group of subjects treated with placebo; the difference between these two values is expressed as the reduction in eosinophil count compared to placebo. This means that the reduction in eosinophil count compared to placebo is equal to “reduction in eosinophil count compared to baseline” minus the change in eosinophil count in the placebo group. In some embodiments, the reduction in eosinophil count refers to the median. In some embodiments, the reduction in eosinophil count refers to the mean. In some embodiments, the reduction in eosinophil count refers to the median change from baseline, expressed as a percentage.
[0108] In some implementations, a reduction in eosinophil count refers to the difference between the median change (in percentage) from baseline in a group of subjects treated with the compound and the median change (in percentage) from baseline in a group of subjects treated with placebo.
[0109] In some embodiments of the invention, a reduction in eosinophil count (compared to baseline) is determined compared to placebo. In some embodiments of the invention, a reduction in eosinophil count is determined compared to baseline. In some embodiments of the invention, a reduction in FeNO level (compared to baseline) is determined compared to baseline, where baseline refers to the subject's isolated baseline.
[0110] In some embodiments of the invention, the eosinophil count is reduced by at least 30%. In some embodiments of the invention, the eosinophil count is reduced by at least 30% relative to the median of a group of subjects. In some embodiments of the invention, the eosinophil count is reduced by at least 30% relative to the mean of a group of subjects. In some embodiments of the invention, the eosinophil count is reduced by at least 35%. In some embodiments of the invention, the eosinophil count is reduced by at least 35% relative to the median of a group of subjects. In some embodiments of the invention, the eosinophil count is reduced by at least 35% relative to the mean of a group of subjects. In some embodiments of the invention, the eosinophil count is reduced by at least 40%. In some embodiments of the invention, the eosinophil count is reduced by at least 40% relative to the median of a group of subjects. In some embodiments of the invention, the eosinophil count is reduced by at least 40% relative to the mean of a group of subjects. Exemplary ranges for the reduction in eosinophil count are 30% to 80%; 35% to 80%; and 40% to 80%.
[0111] In some embodiments, the decrease in eosinophil count occurs within 4 weeks after compound administration. In some embodiments, the decrease in eosinophil count occurs within 2 weeks after compound administration. In some embodiments, the decrease in eosinophil count occurs within 1 week after compound administration. In some embodiments, the decrease in eosinophil count occurs within 3 days after compound administration. In some embodiments, the decrease in eosinophil count occurs within 1 day after compound administration.
[0112] In some embodiments, the compound that binds IL-13 and TSLP and reduces eosinophil count is a peptide (such as an antibody or antibody fragment). In some embodiments, the compound that binds IL-13 and TSLP and reduces eosinophil count is a peptide, wherein the peptide comprises or consists of at least four ISVDs, wherein two ISVDs specifically bind IL-13 and two ISVDs specifically bind TSLP, wherein each of the at least four ISVDs comprises three complementarity-determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptide linkers, and wherein:
[0113] The first ISVD includes:
[0114] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:7, CDR2 is the amino acid sequence of SEQ ID NO:12, and CDR3 is the amino acid sequence of SEQ ID NO:17;
[0115] The second ISVD includes:
[0116] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:8, CDR2 is the amino acid sequence of SEQ ID NO:13, and CDR3 is the amino acid sequence of SEQ ID NO:18;
[0117] The third ISVD includes:
[0118] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:9, CDR2 is the amino acid sequence of SEQ ID NO:14, and CDR3 is the amino acid sequence of SEQ ID NO:19.
[0119] The fourth ISVD includes:
[0120] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:11, CDR2 is the amino acid sequence of SEQ ID NO:16, and CDR3 is the amino acid sequence of SEQ ID NO:21.
[0121] In some embodiments, the compound that combines IL-13 and TSLP and reduces eosinophil count contains or consists of the amino acid sequence of SEQ ID NO:1.
[0122] 5.2.3 Increase in FEV1
[0123] Increased FEV1 levels indicate better lung function and are therefore beneficial for patients with lung diseases (e.g., asthma). In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0124] In this invention, the increase in FEV1 (compared to baseline) is determined compared to a control (such as baseline or placebo). In some embodiments of the invention, FEV1 increases by at least 0.05 L. In some embodiments of the invention, FEV1 increases by at least 0.07 L. In some embodiments of the invention, FEV1 increases by at least 0.1 L. In some embodiments of the invention, FEV1 increases by at least 0.15 L. In some embodiments of the invention, FEV1 increases by at least 0.2 L. In some embodiments of the invention, FEV1 increases by at least 0.25 L. In some embodiments of the invention, FEV1 increases by at least 0.3 L. Exemplary ranges for FEV1 increase are 0.07 L to 0.3 L; 0.1 L to 0.3 L; 0.15 L to 0.3 L; 0.2 L to 0.3 L; and 0.25 L to 0.3 L.
[0125] This invention provides a compound combining IL-13 and TSLP for use in treating lung disease in a subject, wherein FEV1 is increased by at least 0.05 L compared to placebo. This invention provides a compound combining IL-13 and TSLP for use in treating lung disease in a subject, wherein FEV1 is increased by at least 0.07 L compared to placebo. This invention provides a compound combining IL-13 and TSLP for use in treating lung disease in a subject, wherein FEV1 is increased by at least 0.1 L compared to placebo.
[0126] In some embodiments, the increase in FEV1 occurs within 4 weeks after compound administration. In some embodiments, the increase in FEV1 occurs within 2 weeks after compound administration. In some embodiments, the increase in FEV1 occurs within 1 week after compound administration.
[0127] In some embodiments, the compound that binds IL-13 and TSLP and increases FEV1 is a peptide (such as an antibody or antibody fragment). In some embodiments, the compound that binds IL-13 and TSLP and increases FEV1 is a peptide comprising or consisting of at least four ISVDs, wherein two ISVDs specifically bind IL-13 and two ISVDs specifically bind TSLP, wherein each of the at least four ISVDs comprises three complementarity-determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptide linkers, and wherein:
[0128] The first ISVD includes:
[0129] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:7, CDR2 is the amino acid sequence of SEQ ID NO:12, and CDR3 is the amino acid sequence of SEQ ID NO:17;
[0130] The second ISVD includes:
[0131] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:8, CDR2 is the amino acid sequence of SEQ ID NO:13, and CDR3 is the amino acid sequence of SEQ ID NO:18;
[0132] The third ISVD includes:
[0133] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:9, CDR2 is the amino acid sequence of SEQ ID NO:14, and CDR3 is the amino acid sequence of SEQ ID NO:19.
[0134] The fourth ISVD includes:
[0135] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:11, CDR2 is the amino acid sequence of SEQ ID NO:16, and CDR3 is the amino acid sequence of SEQ ID NO:21.
[0136] In some implementations, IL-13 and TSLP are combined and increased The compounds of FEV1 contain or consist of the amino acid sequence of SEQ ID NO:1.
[0137] 5.2.4 Reduction of airway inflammation
[0138] A reduction in airway inflammation indicates better lung function and is therefore beneficial for patients with lung diseases (e.g., asthma). In some embodiments, the airway inflammation is type 2 airway inflammation. In this invention, a reduction in airway inflammation can be determined by analyzing clinical parameters, particularly FeNO, eosinophil count, and FEV1. The reduction or increase of those parameters is determined compared to a baseline or placebo control (as explained above for individual clinical parameters).
[0139] In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 18 ppb and a reduction in eosinophil count of at least 30%. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 18 ppb and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 18 ppb, a reduction in eosinophil count of at least 30%, and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 18 ppb, a reduction in eosinophil count of at least 30%, and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L. Exemplary ranges are a reduction in FeNO of 18 ppb to 70 ppb, a reduction in eosinophil count of 30% to 80%, and an increase in FEV1 of 0.07 L to 0.3 L.
[0140] In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 20 ppb and a reduction in eosinophil count of at least 30%. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 20 ppb and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 20 ppb, a reduction in eosinophil count of at least 30%, and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L.
[0141] In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 30 ppb and a reduction in eosinophil count of at least 30%. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 30 ppb and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 30 ppb, a reduction in eosinophil count of at least 30%, and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L.
[0142] In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 40 ppb and a reduction in eosinophil count of at least 30%. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 40 ppb and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L. In some embodiments, airway inflammation is characterized by a reduction in FeNO of at least 40 ppb, a reduction in eosinophil count of at least 30%, and an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L.
[0143] In some embodiments, airway inflammation is characterized by a reduction of FeNO by at least 18 ppb, a reduction of eosinophil count by at least 30%, an increase in forced expiratory volume in one second (FEV1) by at least 0.07 L, and a reduction in one or more of the following levels: IL-5, CCL26 (eosinophil chemokine-3), TARC (CCL17), and IgE (serum).
[0144] In some embodiments, airway inflammation is characterized by a reduction of FeNO by at least 20 ppb, a reduction of eosinophil count by at least 30%, an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, and a reduction in one or more of the following levels: IL-5, CCL26 (eosinophil chemokine-3), TARC (CCL17), and IgE (serum).
[0145] In some embodiments, airway inflammation is characterized by a reduction of FeNO by at least 30 ppb, a reduction of eosinophil count by at least 30%, an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, and a reduction in one or more of the following levels: IL-5, CCL26 (eosinophil chemokine-3), TARC (CCL17), and IgE.
[0146] In some embodiments, airway inflammation is characterized by a reduction of FeNO by at least 40 ppb, a reduction of eosinophil count by at least 30%, an increase in forced expiratory volume in one second (FEV1) by at least 0.07 L, and a reduction in one or more of the following levels: IL-5, CCL26 (eosinophil chemokine-3), TARC (CCL17), and IgE (serum).
[0147] In some embodiments, reduction of airway inflammation occurs within 4 weeks after compound administration. In some embodiments, reduction of airway inflammation occurs within 2 weeks after compound administration. In some embodiments, reduction of airway inflammation occurs within 1 week after compound administration.
[0148] In some embodiments, the compound that binds IL-13 and TSLP and reduces airway inflammation is a peptide (such as an antibody or antibody fragment). In some embodiments, the compound that binds IL-13 and TSLP and reduces airway inflammation is a peptide comprising or consisting of at least four ISVDs, wherein two ISVDs specifically bind IL-13 and two ISVDs specifically bind TSLP, wherein each of the at least four ISVDs comprises three complementarity-determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptide linkers, and wherein:
[0149] The first ISVD includes:
[0150] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:7, CDR2 is the amino acid sequence of SEQ ID NO:12, and CDR3 is the amino acid sequence of SEQ ID NO:17;
[0151] The second ISVD includes:
[0152] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:8, CDR2 is the amino acid sequence of SEQ ID NO:13, and CDR3 is the amino acid sequence of SEQ ID NO:18;
[0153] The third ISVD includes:
[0154] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:9, CDR2 is the amino acid sequence of SEQ ID NO:14, and CDR3 is the amino acid sequence of SEQ ID NO:19.
[0155] The fourth ISVD includes:
[0156] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:11, CDR2 is the amino acid sequence of SEQ ID NO:16, and CDR3 is the amino acid sequence of SEQ ID NO:21.
[0157] In some embodiments, the compound that combines IL-13 and TSLP and reduces airway inflammation comprises or consists of the amino acid sequence of SEQ ID NO:1.
[0158] 5.2.5 Management of airway inflammation
[0159] This invention can be used to manage airway inflammation. In some embodiments, managing airway inflammation includes reducing FeNO levels to less than 40 ppb. In some embodiments, managing airway inflammation includes reducing FeNO levels to less than 35. In some embodiments, managing airway inflammation includes reducing FeNO levels to less than 30. In some embodiments, managing airway inflammation includes reducing FeNO levels to less than 25. In some embodiments, managing airway inflammation includes reducing FeNO levels to less than 20.
[0160] In some implementations, managing airway inflammation includes reducing FeNO levels to less than 40 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶. 9 FeNO levels are measured in cells per L. In some implementations, managing airway inflammation includes reducing FeNO levels to less than 35 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶ cells / L. 9 FeNO levels are measured in cells per L. In some implementations, managing airway inflammation includes reducing FeNO levels to less than 30 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶ cells / L. 9 FeNO levels are measured in cells per L. In some implementations, managing airway inflammation includes reducing FeNO levels to less than 25 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶ cells / L. 9FeNO levels are measured in cells per L. In some implementations, managing airway inflammation includes reducing FeNO levels to less than 20 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶ cells / L. 9 Cells / L
[0161] In some embodiments, managing airway inflammation further includes reducing one or more of the following levels: IL-5, CCL26 (eosinophil chemokine-3), TARC (CCL17), and IgE.
[0162] This invention can be used to manage type 2 airway inflammation. In some embodiments, managing type 2 airway inflammation includes reducing FeNO levels to less than 40 ppb. In some embodiments, managing type 2 airway inflammation includes reducing FeNO levels to less than 35. In some embodiments, managing type 2 airway inflammation includes reducing FeNO levels to less than 30. In some embodiments, managing type 2 airway inflammation includes reducing FeNO levels to less than 25. In some embodiments, managing type 2 airway inflammation includes reducing airway inflammation to less than 20.
[0163] In some implementations, managing type 2 airway inflammation includes reducing FeNO levels to less than 40 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶. 9 FeNO levels are measured in cells per L. In some implementations, managing type 2 airway inflammation includes reducing FeNO levels to less than 35 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶ cells / L. 9 FeNO levels are measured in cells per L. In some implementations, managing type 2 airway inflammation includes reducing FeNO levels to less than 30 ppb and the eosinophil count in the blood to less than 0.2 × 10⁻⁶ cells / L. 9 FeNO levels are measured in cells per L. In some implementations, managing type 2 airway inflammation includes reducing FeNO levels to less than 25 ppb and reducing the blood eosinophil count to less than 0.2 × 10⁻⁶ cells / L. 9 FeNO levels are measured in cells per L. In some implementations, managing type 2 airway inflammation includes reducing FeNO levels to less than 20 ppb and the eosinophil count in the blood to less than 0.2 × 10⁻⁶ cells / L. 9 Cells / L
[0164] 5.3 Compounds for use according to the invention
[0165] The compound used in this invention to bind TSLP and IL-13 may be a polypeptide. Suitable polypeptides have been described in patent application WO 2021116182, which is incorporated herein by reference in its entirety.
[0166] In some embodiments, the polypeptide is an antibody or antibody fragment. An exemplary polypeptide used in this invention is a polypeptide comprising an immunoglobulin single variable domain (ISVD). ISVDs binding TSLP and IL-13 can be found in Tables A-1 to A-6 of WO2021116182.
[0167] In some embodiments, the polypeptide comprises or consists of at least four ISVDs, wherein two ISVDs specifically bind to IL-13 and two ISVDs specifically bind to TSLP, wherein each of the at least four ISVDs comprises three complementarity-determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptide linkers, and wherein:
[0168] The first ISVD includes:
[0169] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:7, CDR2 is the amino acid sequence of SEQ ID NO:12, and CDR3 is the amino acid sequence of SEQ ID NO:17;
[0170] The second ISVD includes:
[0171] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:8, CDR2 is the amino acid sequence of SEQ ID NO:13, and CDR3 is the amino acid sequence of SEQ ID NO:18;
[0172] The third ISVD includes:
[0173] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:9, CDR2 is the amino acid sequence of SEQ ID NO:14, and CDR3 is the amino acid sequence of SEQ ID NO:19.
[0174] The fourth ISVD includes:
[0175] CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:11, CDR2 is the amino acid sequence of SEQ ID NO:16, and CDR3 is the amino acid sequence of SEQ ID NO:21.
[0176] SEQ ID NO:7 is GRTFSSYRMG; SEQ ID NO:12 is ALSGDGYSTY; SEQ ID NO:17 is KLQYVSGWSYDYPY.
[0177] SEQ ID NO:8 is GFTFNNYAMK; SEQ ID NO:13 is SITTGGGSTD; SEQ ID NO:18 is VPFGYYSEHFSGLSFDY.
[0178] SEQ ID NO:9 is GSGFGVNILY; SEQ ID NO:14 is SITSGGITN; SEQ ID NO:19 is RNIFDGTTE.
[0179] SEQ ID NO:11 is GFTFADYDYDIG; SEQ ID NO:16 is CISNRDGSTY; SEQ ID NO:21 is EIHCDDYGVENFDFDP.
[0180] In some embodiments, the compound comprises:
[0181] The first ISVD contains the amino acid sequence of SEQ ID NO:2;
[0182] The second ISVD contains the amino acid sequence of SEQ ID NO:3;
[0183] The third ISVD contains the amino acid sequence of SEQ ID NO:4; and
[0184] The fourth ISVD contains the amino acid sequence of SEQ ID NO:6.
[0185] In some embodiments, the order of the above ISVDs indicates their relative positions to each other from the N-terminus to the C-terminus of the polypeptide.
[0186] In some embodiments, the compound comprises an additional ISVD that binds to human serum albumin, wherein the additional ISVD comprises: CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:10, CDR2 is the amino acid sequence of SEQ ID NO:15, and CDR3 is the amino acid sequence of SEQ ID NO:20. In some embodiments, the additional ISVD is located between the third and fourth ISVDs mentioned above.
[0187] In some embodiments, the compound comprises:
[0188] The first ISVD contains the amino acid sequence of SEQ ID NO:2;
[0189] The second ISVD contains the amino acid sequence of SEQ ID NO:3;
[0190] The third ISVD contains the amino acid sequence of SEQ ID NO:4;
[0191] The fourth ISVD contains the amino acid sequence of SEQ ID NO:6;
[0192] And another ISVD, which binds to human serum albumin and contains the amino acid sequence of SEQ ID NO:5.
[0193] An exemplary peptide that binds TSLP and IL-13 is SAR443765 (also known as lunsekimig) (SEQ ID NO:1). In some embodiments, the peptide that binds TSLP and IL-13 is SAR443765 (SEQ ID NO:1).
[0194] SEQ ID NO:1 is:
[0195] .
[0196] 5.3.1 Immunoglobulin Single Variable Domain
[0197] As described above, in some embodiments, the polypeptide used in this invention is a polypeptide containing an immunoglobulin single variable domain (ISVD).
[0198] The term "immunoglobulin single variable domain" (ISVD) is used interchangeably with "single variable domain" and defines an immunoglobulin molecule in which an antigen-binding site is located on a single immunoglobulin domain and formed therefrom. This distinguishes ISVDs from "conventional" immunoglobulins (e.g., monoclonal antibodies) or fragments thereof (e.g., Fab, Fab', F(ab')2, scFv, discFv), where two immunoglobulin domains, particularly two variable domains, interact to form an antigen-binding site. Typically, in conventional immunoglobulins, the heavy chain variable domain (V... H ) and light chain variable structural domain (V L ) interact to form antigen-binding sites. In this case, V H and V L The complementary determinant regions (CDRs) of the two will facilitate the formation of antigen binding sites, meaning that a total of 6 CDRs will participate in the formation of antigen binding sites.
[0199] Given the above definitions, the antigen-binding domain of a conventional four-chain antibody (such as IgG, IgM, IgA, IgD, or IgE molecules; known in the art) or the antigen-binding domain of a Fab fragment, F(ab')2 fragment, Fv fragment (such as disulfide-linked Fv or scFv fragments) or a biantibody (all known in the art) derived from such a conventional four-chain antibody is generally not considered an ISVD because, in these cases, binding to the corresponding epitope of the antigen typically does not occur through a single immunoglobulin domain, but rather through a pair of associated immunoglobulin domains, such as light and heavy chain variable domains, i.e., through the V-shaped structure of the immunoglobulin domains that bind together to the respective epitopes of the antigen. H -V L It happened.
[0200] In contrast, ISVDs can specifically bind to antigenic epitopes without pairing with other immunoglobulin variable domains. The binding site of ISVDs consists of a single V... H A single V HH Or a single V L Domain formation.
[0201] Therefore, the single variable structural domain can be a sequence of light chain variable structural domains (e.g., V). L Sequences) or suitable fragments thereof; or heavy-chain variable domain sequences (e.g., V H Sequence or V HH (sequence) or a suitable fragment thereof; as long as it can form a single antigen-binding unit (i.e., a functional antigen-binding unit consisting essentially of a single variable domain, such that the single antigen-binding domain does not need to interact with another variable domain to form a functional antigen-binding unit).
[0202] ISVDs can be, for example, heavy chain ISVDs (such as V...). H V HH ), including camel-like V H Or humanized V HH In one implementation, it is V HH Including camel-like V H Or humanized V HH Heavy chain ISVDs can be derived from conventional four-chain antibodies or heavy chain antibodies.
[0203] For example, an ISVD can be a single-domain antibody (or an amino acid sequence suitable for use as a single-domain antibody), "dAb" or dAb (or an amino acid sequence suitable for use as a dAb) or (as defined herein, and including but not limited to V) HH ); other single variable domains, or any suitable fragment of any of them.
[0204] Specifically, ISVD can be (e.g. V) HH Including humanized V HH or camel-like V H (or a suitable fragment thereof.) and It is a registered trademark of Sanofi or its affiliates.
[0205] “V HH "Structured domain" is also called V HH V HH Antibody fragments and V HH Antibodies, initially described as "heavy chain antibodies" (i.e., "light chain-less antibodies"; Hamers-Casterman et al., Nature 363:446-448, 1993), are antigen-binding immunoglobulin variable domains. The term "V" has been chosen. HH "V" refers to these variable domains in conjunction with the heavy chain variable domains present in conventional 4-chain antibodies (which are referred to in this paper as "V"). H The structural domain”) and the light chain variable structural domain (referred to in this paper as “V”) present in conventional 4-chain antibodies. L Distinguish between "structural domain" and "structural domain". For V HH For further description, see Muyldermans’ review article (Reviews in Molecular Biotechnology 74:277-302, 2001).
[0206] Typically, immunoglobulin production involves immunizing laboratory animals, fusing immunoglobulin-producing cells to create hybridomas, and screening for the required specificity. Alternatively, immunoglobulins can be generated by screening natural or synthetic libraries (e.g., via phage display).
[0207] The generation of immunoglobulin sequences (e.g.) This method has been widely described in various publications, with WO 94 / 04678, Hamers-Casterman et al. 1993, and Muyldermans, 2001 serving as examples. In these methods, camels are immunized with a target antigen to induce an immune response against the target antigen. A library of nanoantibodies obtained from the immunization is then further screened for nanoantibodies that bind to the target antigen.
[0208] In these cases, antibody generation requires purified antigens for immunization and / or screening. Antigens can be purified from natural sources or during recombinant production.
[0209] Immunization and / or screening of immunoglobulin sequences can be performed using peptide fragments of such antigens.
[0210] This invention can use immunoglobulin sequences of different origins, including mouse, rat, rabbit, donkey, human, and cameloid immunoglobulin sequences. This invention can also use fully human sequences, humanized sequences, or chimeric sequences. For example, this invention uses cameloid immunoglobulin sequences and humanized cameloid immunoglobulin sequences or camel-derived domain antibodies, such as those described by Ward et al. (see, for example, WO 94 / 04678 and Davies et al.). Riechmann (1994 and 1996) described camel-derived dAb. Furthermore, in some embodiments, the invention also uses fused immunoglobulin sequences, for example, to form multivalent and / or multispecific constructs (for constructs containing one or more V...). HH Multivalent and multispecific polypeptides and their formulations with domains, see also Conrath et al., J. Biol. Chem., vol. 276, 10. 7346-7350, 2001, and, for example, WO 96 / 34103 and WO 99 / 23221; and immunoglobulin sequences containing tags or other functional parts (e.g., toxins, markers, radiochemicals, etc.), which may be derived from the immunoglobulin sequences of the compounds used in this invention.
[0211] 5.3.2 Antibodies
[0212] As described above, in some embodiments, the polypeptide used in this invention is an antibody. Antibodies that bind TSLP and IL-13 can be found in Venkataramani et al. (Biochem Biophys Res Commun. 26 Sep 2018; 504(1):19-24).
[0213] 5.3.3 Binding / Blocking
[0214] The compounds of the present invention bind to TSLP and IL-13. In some embodiments, the compounds of the present invention can block their target molecules. For example, the compounds can block the interaction between IL-13 and IL-13Rα1 (interleukin 13 receptor, α1) and / or the interaction between the IL-13 / IL-13Rα1 complex and IL-4Rα (α-interleukin 4 receptor), and / or the interaction between TSLP and TSLPR (TSLP receptor) and / or the TSLP / TSLPR complex and IL-7Rα (interleukin 7 receptor subunit α). In some embodiments, the compounds of the present invention can block the interaction between IL-13 and IL-13Rα1 (interleukin 13 receptor, α1) and / or the interaction between the IL-13 / IL-13Rα1 complex and IL-4Rα (α-interleukin 4 receptor), and can block the interaction between TSLP and TSLPR (TSLP receptor) and / or the TSLP / TSLPR complex and IL-7Rα (interleukin 7 receptor subunit α).
[0215] In some embodiments, the compounds used in this invention may combine human IL-13 (Uniprot accession number P35225) and human TSLP (Uniprot accession number Q969D9). In some embodiments, the compounds used in this invention may combine IL-13 and TSLP from other mammals, such as mice, rats, rabbits, cats, dogs, goats, sheep, horses, pigs, non-human primates (such as cynomolgus monkeys (also referred to herein as "cyno")) or camelids (such as llamas or alpacas).
[0216] Regarding the compounds of this invention, binding to IL-13 and TSLP refers to specific binding to IL-13 and TSLP. The binding of a compound to its target can be determined based on affinity. Affinity represents the strength or stability of molecular interactions. Affinity is typically given by KD or the dissociation constant, in units of mol / L (or M). Affinity can also be expressed as the association constant KA, which is equal to 1 / KD and in units of (mol / L). -1 (or M) -1 ).
[0217] Affinity is a measure of the strength of binding between a part of the target molecule and its binding site: the lower the KD value, the stronger the binding between the target molecule and the target part.
[0218] Typically, the binding unit used in this invention binds to its target with the following dissociation constant (KD): 10 -5 Up to 10 - 12 mol / L or less, or 10 -7 Up to 10 -12 mol / L or less, or 10 -8 Up to 10 -12 mol / L (i.e., the association constant (KA) is 10) 5 Up to 10 12 L / mol or greater, or 10 7 Up to 10 12 L / mol or greater, or 10 8 Up to 10 12 L / mol).
[0219] It is generally considered that anything greater than 10 -4 KD value of mol / L (or any value less than 10 mol / L) 4 The KA value (L / mol) indicates non-specific interactions.
[0220] KD, which is considered to have specific biological interactions (such as the binding of immunoglobulin sequences to antigens), is typically in the range of 10. -5 mol / L (10000nM or 10μM) to 10 -12 Within the range of mol / L (0.001 nM or 1 pM) or smaller.
[0221] Therefore, specific / selective binding may mean that, using the same measurement method (e.g., SPR), the compound binds at a rate of 10... -5 Up to 10 -12 KD values of mol / L or lower bind to IL13 and / or TSLP, and at a concentration greater than 10 mol / L. -4 A KD value of mol / L is associated with the binding of relevant cytokines. An example of an IL13-associated target is human IL4. An example of a TSLP-associated cytokine is human IL7. Therefore, in some embodiments, the compounds used in this invention are expressed at a concentration of 10 mol / L. -5 Up to 10 -12 KD values of mol / L or lower bind to IL13 and at a concentration greater than 10 mol / L. -4 The KD value of mol / L binds to IL4 of the same species and at a rate of 10 -5 Up to 10 -12 KD values of mol / L or less bind with TSLP and at a concentration greater than 10-4 The KD value of mol / L is associated with the binding of human IL7 of the same species.
[0222] In some embodiments, the peptides used in this invention have at least half or at least the same binding affinity for human IL13 and human TSLP compared to the peptides consisting of the amino acid sequence of SEQ ID NO:1, wherein the binding affinity is measured using the same method (such as SPR).
[0223] Specific binding to a specific target from a particular species does not preclude the binding unit from specifically binding to similar targets from different species. For example, specific binding to human IL13 does not preclude the binding unit (or a polypeptide containing said binding unit) from specifically binding to IL13 from cynomolgus monkeys. Similarly, specific binding to human TSLP, for example, does not preclude the binding unit (or a polypeptide containing said binding unit) from specifically binding to TSLP from cynomolgus monkeys (“cyno”).
[0224] The binding unit can be determined by any suitable means known per se (including, for example, Scatchard analysis and / or competitive binding assays (such as radioimmunoassay (RIA), enzyme immunoassay (EIA) and sandwich competitive assays and their various variants known in the art); as well as other techniques mentioned herein.
[0225] The dissociation constant can be either actual or apparent, as will be clear to those skilled in the art. Methods for determining the dissociation constant are clear to those skilled in the art and include, for example, the techniques mentioned below. In this regard, it will also be clear that it may be impossible to measure a value greater than 10. -4 mol / L or 10 -3 mol / L (e.g., 10 mol / L) -2 The dissociation constant (mol / L). Optionally, as those skilled in the art will also know, the (actual or apparent) dissociation constant can be calculated based on the (actual or apparent) association constant (KA) through the relationship [KD = 1 / KA].
[0226] The affinity of molecular interactions between two molecules can be measured using various techniques known to them, such as the well-known surface plasmon resonance (SPR) biosensor technique (see, for example, Ober et al. 2001, Intern. Immunology 13:1551-1559). As used herein, the term “surface plasmon resonance” refers to an optical phenomenon that allows for the analysis of real-time, biospecific interactions by detecting changes in protein concentration in a biosensor matrix, where one molecule is immobilized on a biosensor chip and another molecule flows through the immobilized molecule under flow conditions, thereby generating kon k off Measured values, and thus K. D (or K) A ) value. For example, this can be done using well-known The system (BIAcore International AB, a GE Healthcare company, Uppsala, Sweden and Piscatave, New Jersey) was used. For further description, see Jonsson et al. (1993, Ann. Biol. Clin. 51:19-26), Jonsson et al. (1991 Biotechniques 11:620-627), Johnson et al. (1995, J. Mol. Recognit. 8:125-131) and Johnson et al. (1991, Anal. Biochem. 198:268-277).
[0227] Another well-known biosensor technique for determining the affinity of biomolecular interactions is biolayer interferometry (BLI) (see, for example, Abdiche et al. 2008, Anal. Biochem. 377:209-217). As used herein, the term “biolayer interferometry” or “BLI” refers to a label-free optical technique that analyzes the interference pattern of light reflected from two surfaces: an inner reference layer (reference beam) and a layer of immobilized proteins on the biosensor tip (signal beam). Variations in the number of molecules bound to the biosensor tip result in a shift in the interference pattern, reported as a wavelength shift (nm), the magnitude of which is a direct measure of the number of molecules bound to the surface of the biosensor tip. Because interactions can be measured in real time, association and dissociation rates, as well as affinity, can be determined. For example, BLI can use well-known... The system (ForteBio, a division of Pall Life Sciences, Menlo Park, USA) is used for this purpose.
[0228] Alternatively, it can be used in kinetic repulsion assays (KinExA) (see, for example, Drake et al. 2004, Anal. Biochem., 328:35-43). The platform (Sapidyne Instruments Inc., Boise, USA) measures affinity. As used herein, the term "KinExA" refers to a solution-based method for measuring the true equilibrium binding affinity and kinetics of unmodified molecules. An equilibrium solution of an antibody / antigen complex is passed through a column containing beads pre-coated with the antigen (or antibody), allowing the free antibody (or antigen) to bind to the coated molecule. Detection of the thus captured antibody (or antigen) is performed using a fluorescently labeled protein that binds the antibody (or antigen).
[0229] Immunoassay systems provide a platform for automated bioanalysis and rapid sample turnaround (Fraley et al. 2013, Bioanalysis 5:1765-74).
[0230] 5.3.4 Nucleic Acid Molecules
[0231] In some embodiments, the present invention relates to nucleic acids for use in treating a subject's lung disease, wherein the nucleic acid encodes a compound that binds IL-13 and TSLP, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a placebo. In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0232] A “nucleic acid molecule” (used interchangeably with “nucleic acid”) is a chain of monomeric nucleotides linked together by a phosphate backbone to form a nucleotide sequence. Nucleic acids can be used to transform / transfect host cells or host organisms, for example, to express and / or produce polypeptides. Suitable hosts or host cells for the purpose of production will be clear to those skilled in the art and can be, for example, any suitable fungus, prokaryotic or eukaryotic cell or cell line or any suitable fungus, prokaryotic or eukaryotic organism. Hosts or host cells containing nucleic acids encoding the polypeptides of the present invention are also covered by the present invention.
[0233] Nucleic acid can be, for example, DNA, RNA, or a hybrid thereof, and may also contain (e.g., chemically modified) nucleotides, such as PNA. It can be single-stranded or double-stranded. In one embodiment, it is in the form of double-stranded DNA. For example, the nucleotide sequence of the present invention can be genomic DNA or cDNA.
[0234] The nucleic acids of the present invention can be prepared or obtained in a manner known per se, and / or can be isolated from suitable natural sources. Nucleotide sequences encoding naturally occurring (poly)peptides can, for example, be subjected to site-directed mutagenesis to provide nucleic acid molecules encoding polypeptides with sequence variations. Furthermore, it will be apparent to those skilled in the art that, in order to prepare nucleic acids, several nucleotide sequences (such as at least one nucleotide sequence encoding a target moiety) can be linked together in a suitable manner with nucleic acids, for example, encoding one or more adapters.
[0235] The techniques for generating nucleic acids will be clear to technicians and may include, for example, but not limited to, automated DNA synthesis; site-directed mutagenesis; combining two or more naturally occurring and / or synthetic sequences (or two or more portions thereof) to introduce mutations that result in the expression of truncated expression products; introducing one or more restriction sites (e.g., to generate easily digestible and / or linked boxes and / or regions using suitable restriction enzymes); and / or introducing mutations via PCR reactions using one or more “mismatched” primers.
[0236] 5.3.5 Composition
[0237] The present invention also provides pharmaceutical compositions for use in the present invention, wherein the pharmaceutical composition comprises at least one compound that binds to TSLP and IL-13, and / or at least one nucleic acid molecule encoding a compound that binds to TSLP and IL-13. The composition may further comprise at least one pharmaceutically acceptable carrier, diluent, or excipient and / or adjuvant, and optionally comprises one or more additional pharmaceutically active peptides and / or compounds.
[0238] In some embodiments, the present invention provides pharmaceutical compositions comprising compounds for use in treating a lung disease in a subject, in combination with IL-13 and TSLP, wherein the composition further comprises at least one pharmaceutically acceptable carrier, diluent, or excipient and / or adjuvant, and optionally comprises one or more additional pharmaceutically active peptides and / or compounds, wherein treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo. In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0239] In some embodiments, the present invention provides pharmaceutical compositions comprising compounds for use in treating a lung disease in a subject, combining IL-13 and TSLP, wherein the composition further comprises at least one pharmaceutically acceptable carrier, diluent, or excipient and / or adjuvant, and optionally comprises one or more additional pharmaceutically active peptides and / or compounds, wherein treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to placebo. In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0240] In some embodiments, the present invention provides pharmaceutical compositions comprising compounds for use in treating a lung disease in a subject, combining IL-13 and TSLP, wherein the composition further comprises at least one pharmaceutically acceptable carrier, diluent, or excipient and / or adjuvant, and optionally comprises one or more additional pharmaceutically active peptides and / or compounds, wherein treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to placebo. In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0241] In some embodiments, the present invention provides pharmaceutical compositions comprising compounds for use in treating a lung disease in a subject, in combination with IL-13 and TSLP, wherein the composition further comprises at least one pharmaceutically acceptable carrier, diluent, or excipient and / or adjuvant, and optionally comprises one or more additional pharmaceutically active peptides and / or compounds, wherein treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to placebo. In some embodiments, the lung disease is an inflammatory disease. In some embodiments, the lung disease is asthma. In some embodiments, the asthma is hypereosinophilic asthma. In some embodiments, the asthma is hypoeosinophilic asthma.
[0242] 5.4 Scheme of the present invention
[0243] For illustrative purposes, the following exemplary embodiments of the present invention are provided.
[0244] 5.4.1 Compounds combining IL-13 and TSLP for use in the treatment of lung diseases
[0245] These implementations involve a compound combining IL-13 and TSLP for use in treating lung disease in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
[0246] FeNO levels + time points
[0247] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 18 ppb compared to placebo within 4 weeks following compound administration.
[0248] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 18 ppb compared to placebo within 2 weeks after compound administration.
[0249] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 18 ppb compared to placebo.
[0250] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 20 ppb compared to placebo within 4 weeks after compound administration.
[0251] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 20 ppb compared to placebo within 2 weeks after compound administration.
[0252] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 20 ppb compared to placebo.
[0253] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 25 ppb compared to placebo within 4 weeks after compound administration.
[0254] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 25 ppb compared to placebo within 2 weeks after compound administration.
[0255] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 25 ppb compared to placebo within one week after compound administration.
[0256] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 30 ppb compared to placebo within 4 weeks following compound administration.
[0257] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 30 ppb compared to placebo within 2 weeks after compound administration.
[0258] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 30 ppb compared to placebo.
[0259] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 35 ppb compared to placebo within 4 weeks after compound administration.
[0260] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 35 ppb compared to placebo within 2 weeks after compound administration.
[0261] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 35 ppb compared to placebo.
[0262] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 40 ppb compared to placebo within 4 weeks after compound administration.
[0263] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 40 ppb compared to placebo within 2 weeks after compound administration.
[0264] In some implementations, treatment reduced exhaled nitric oxide (FeNO) levels by at least 40 ppb compared to placebo within one week after compound administration.
[0265] FeNO baseline level
[0266] In some implementations, the treatment is applied to subjects with a baseline (before compound administration) FeNO level of at least 25.
[0267] In some implementations, the treatment is applied to subjects with a baseline (before compound administration) FeNO level of at least 30.
[0268] In some implementations, the treatment is applied to subjects whose baseline (before compound administration) FeNO level is at least 40.
[0269] In some implementations, the treatment is applied to subjects with a baseline (before compound administration) FeNO level of at least 50.
[0270] In some implementations, the treatment is applied to subjects whose baseline (before compound administration) FeNO level is at least 60.
[0271] In some implementations, the treatment is applied to subjects whose baseline (before compound administration) FeNO level is at least 70.
[0272] In some implementations, the treatment is applied to subjects who manage at least 25% of their baseline (before compound administration) FeNO levels.
[0273] In some implementations, the treatment is applied to subjects who manage at least 30% of their baseline (before compound administration) FeNO levels.
[0274] In some implementations, the treatment is applied to subjects who manage at least 40% of their baseline (before compound administration) FeNO levels.
[0275] In some implementations, the treatment is applied to subjects who manage at least 50% of their baseline (before compound administration) FeNO levels.
[0276] In some implementations, the treatment is applied to subjects who manage at least 60% of their baseline (before compound administration) FeNO levels.
[0277] In some implementations, the treatment is applied to subjects who manage at least 70% of their baseline (before compound administration) FeNO levels.
[0278] Eosinophil count + time point
[0279] In some embodiments of the invention, within 4 weeks after administration of the compound, the eosinophil count is reduced by at least 30% compared to placebo.
[0280] In some embodiments of the invention, within 2 weeks after administration of the compound, the eosinophil count is reduced by at least 30% compared to placebo.
[0281] In some embodiments of the invention, within one week after administration of the compound, the eosinophil count is reduced by at least 30% compared to placebo.
[0282] In some embodiments of the invention, within 3 days after administration of the compound, the eosinophil count is reduced by at least 30% compared to placebo.
[0283] In some embodiments of the invention, within one day after administration of the compound, the eosinophil count is reduced by at least 30% compared to a placebo.
[0284] In some embodiments of the invention, within 4 weeks after administration of the compound, the eosinophil count is reduced by at least 35% compared to placebo.
[0285] In some embodiments of the invention, within 2 weeks after administration of the compound, the eosinophil count is reduced by at least 35% compared to placebo.
[0286] In some embodiments of the invention, within one week after administration of the compound, the eosinophil count is reduced by at least 35% compared to placebo.
[0287] In some embodiments of the invention, within 3 days after administration of the compound, the eosinophil count is reduced by at least 35% compared to placebo.
[0288] In some embodiments of the invention, within one day after administration of the compound, the eosinophil count is reduced by at least 35% compared to placebo.
[0289] In some embodiments of the invention, within 4 weeks after administration of the compound, the eosinophil count is reduced by at least 40% compared to placebo.
[0290] In some embodiments of the invention, within 2 weeks after administration of the compound, the eosinophil count is reduced by at least 40% compared to placebo.
[0291] In some embodiments of the invention, within one week after administration of the compound, the eosinophil count is reduced by at least 40% compared to placebo.
[0292] In some embodiments of the invention, within 3 days after administration of the compound, the eosinophil count is reduced by at least 40% compared to placebo.
[0293] In some embodiments of the invention, within one day after administration of the compound, the eosinophil count is reduced by at least 40% compared to placebo.
[0294] FENO level + eosinophil count + time point
[0295] In some implementations, within 4 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 18 ppb and eosinophil counts by at least 30% compared to placebo.
[0296] In some implementations, within 4 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 20 ppb and eosinophil counts by at least 30% compared to placebo.
[0297] In some implementations, within 4 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 30 ppb and eosinophil counts by at least 30% compared to placebo.
[0298] In some implementations, within 4 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 40 ppb and eosinophil counts by at least 30% compared to placebo.
[0299] In some implementations, within 2 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 18 ppb and eosinophil counts by at least 30% compared to placebo.
[0300] In some implementations, within 2 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 20 ppb and eosinophil counts by at least 30% compared to placebo.
[0301] In some implementations, within 2 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 30 ppb and eosinophil counts by at least 30% compared to placebo.
[0302] In some implementations, within 2 weeks of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 40 ppb and eosinophil counts by at least 30% compared to placebo.
[0303] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 18 ppb and eosinophil counts by at least 30% compared to placebo.
[0304] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 20 ppb and eosinophil counts by at least 30% compared to placebo.
[0305] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 30 ppb and eosinophil counts by at least 30% compared to placebo.
[0306] In some implementations, within one week of compound administration, treatment reduced exhaled nitric oxide (FeNO) levels by at least 40 ppb and eosinophil counts by at least 30% compared to placebo.
[0307] SEQ ID NO:1+Asthma
[0308] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0309] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating subjects with hypereosinophilic asthma, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0310] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating hypoeosinophilic asthma in subjects, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0311] SEQ ID NO:1 + Asthma + FeNO Level
[0312] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo, wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0313] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to placebo, wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0314] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to placebo, wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0315] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to placebo, wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0316] SEQ ID NO:1 + Asthma + FeNO Level + Time Point
[0317] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0318] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to a control, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0319] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to a control, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0320] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to a control, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0321] SEQIDNO:1 + Asthma + FeNO Level + Time Point + Placebo
[0322] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0323] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to placebo, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0324] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to placebo, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0325] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to placebo, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0326] SEQ ID NO:1 + Asthma + FeNO Level + Time Point + Baseline
[0327] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is an amino acid sequence comprising SEQ ID NO:1 or a polypeptide consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0328] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0329] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0330] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0331] SEQ ID NO:1 + Asthma + FeNO Level + Person + Baseline
[0332] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to baseline, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0333] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to baseline, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0334] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to baseline, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0335] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to baseline, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0336] SEQ ID NO:1 + Asthma + FeNO Level + Person + Time Point + Baseline
[0337] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0338] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0339] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 30 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0340] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in human subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 40 ppb compared to baseline, wherein the reduction in FeNO level occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0341] SEQ ID NO:1 + Asthma + Eosinophil Count + Time Point
[0342] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0343] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 35% compared to a control, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0344] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 40% compared to a control, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0345] SEQ ID NO:1 + Asthma + Eosinophil Count + Time Point + Placebo
[0346] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a placebo, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0347] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 35% compared to a placebo, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0348] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 40% compared to a placebo, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0349] SEQ ID NO:1 + Asthma + Eosinophil Count + Time Point + Baseline
[0350] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating a subject with asthma, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to baseline, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0351] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 35% compared to baseline, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0352] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating a subject with asthma, wherein the treatment reduces the eosinophil count in the blood by at least 40% compared to baseline, wherein the reduction in the eosinophil count occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, wherein baseline refers to the subject's individual baseline.
[0353] SEQ ID NO:1 + Asthma + Airway Inflammation + Time Point
[0354] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a control, is characterized by a reduction in FeNO by at least 18 ppb, a reduction in eosinophil count by at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) by at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0355] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a control, is characterized by a reduction in FeNO of at least 20 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0356] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a control, is characterized by a reduction in FeNO of at least 30 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0357] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a control, is characterized by a reduction in FeNO of at least 40 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0358] SEQ ID NO:1 + Asthma + Airway Inflammation + Time Point + Placebo
[0359] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a placebo, is characterized by a reduction in FeNO of at least 18 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0360] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a placebo, is characterized by a reduction in FeNO of at least 20 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0361] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a placebo, is characterized by a reduction in FeNO of at least 30 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0362] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in treating asthma in a subject, wherein the treatment reduces airway inflammation, wherein the reduction in airway inflammation, compared to a placebo, is characterized by a reduction in FeNO of at least 40 ppb, a reduction in eosinophil count of at least 30%, and / or an increase in forced expiratory volume in one second (FEV1) of at least 0.07 L, wherein the reduction in airway inflammation occurs within 4 weeks after administration of the compound, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0363] 5.4.2 Methods for treating lung diseases
[0364] The present invention also provides a method for treating a lung disease in a subject, the method comprising administering to the subject an effective amount of a compound that binds IL-13 and TSLP, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control.
[0365] In some embodiments, the present invention provides a method for treating a lung disease in a subject, the method comprising administering to the subject an effective amount of a compound combining IL-13 and TSLP, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
[0366] All embodiments and examples of the compounds described above for use in treating lung diseases in subjects, which combine IL-13 and TSLP (where the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control), can be transferred to a method of treating lung diseases in subjects, the method comprising administering to the subject an effective amount of the compound combining IL-13 and TSLP, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control. This is particularly applicable to reductions in FeNO levels, time points, the nature of the compound, the type of lung disease, and controls. For example, in some embodiments, the present invention provides a method of treating lung diseases in subjects, the method comprising administering to the subject an effective amount of the compound combining IL-13 and TSLP, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb, at least 30 ppb, or at least 40 ppb compared to a control.
[0367] The present invention also provides a method for treating a lung disease in a subject, the method comprising administering to the subject an effective amount of a compound binding IL-13 and TSLP, wherein the treatment reduces the eosinophil count compared to a control.
[0368] In some embodiments, the present invention provides a method for treating a subject with a lung disease, the method comprising administering to the subject an effective amount of a compound combining IL-13 and TSLP, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control.
[0369] All embodiments and examples of the compounds described above for use in treating lung disease in a subject, combining IL-13 and TSLP (wherein the treatment reduces the eosinophil count in the blood compared to a control), can be transferred to a method of treating lung disease in a subject, the method comprising administering to the subject an effective amount of the compound combining IL-13 and TSLP, wherein the treatment reduces the eosinophil count in the blood compared to a control. This is particularly applicable to the reduction in eosinophil count, the time point, the nature of the compound, the type of lung disease, and the control. For example, in some embodiments, the present invention provides a method of treating lung disease in a subject, the method comprising administering to the subject an effective amount of the compound combining IL-13 and TSLP, wherein the treatment reduces the eosinophil count in the blood by at least 35% or at least 40% compared to a control.
[0370] The present invention also provides a method for treating a lung disease in a subject, the method comprising administering to the subject an effective amount of a compound binding IL-13 and TSLP, wherein the treatment reduces airway inflammation. All embodiments and examples given above for the use of compounds binding IL-13 and TSLP in treating a lung disease in a subject (wherein the treatment reduces airway inflammation) can be transferred to a method for treating a lung disease in a subject, the method comprising administering to the subject an effective amount of a compound binding IL-13 and TSLP, wherein the treatment reduces airway inflammation. This is particularly applicable to the definition of airway inflammation reduction, time points, the nature of the compound, the type of lung disease, and controls.
[0371] 5.4.3 Use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases way
[0372] The present invention also provides the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control.
[0373] In some embodiments, the present invention provides the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
[0374] All embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects (where the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control) can be transferred to the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control. This is particularly applicable to reductions in FeNO levels, time points, the nature of the compounds, the type of lung disease, and controls. For example, in some embodiments, the present invention provides the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb, at least 30 ppb, or at least 40 ppb compared to a control.
[0375] The present invention also provides the use of a compound combining IL-13 and TSLP in the preparation of a pharmaceutical composition for treating a lung disease in a subject, wherein the treatment reduces the eosinophil count in the blood compared to a control.
[0376] In some embodiments, the present invention provides the use of a compound combining IL-13 and TSLP in the preparation of a pharmaceutical composition for treating a lung disease in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control.
[0377] All embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects (where the treatment reduces the eosinophil count in the blood compared to a control) can be transferred to the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces the eosinophil count in the blood compared to a control. This is particularly applicable to the reduction in eosinophil count, time point, nature of the compound, type of lung disease, and control. For example, in some embodiments, the present invention provides the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces the eosinophil count in the blood by at least 35% or at least 40% compared to a control.
[0378] This invention also provides the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces airway inflammation. All embodiments and examples given above for compounds combining IL-13 and TSLP for use in treating lung diseases in subjects (wherein the treatment reduces airway inflammation) can be transferred to the use of compounds combining IL-13 and TSLP in the preparation of pharmaceutical compositions for treating lung diseases in subjects, wherein the treatment reduces airway inflammation. This is particularly applicable to the definition of airway inflammation reduction, time points, properties of the compounds, types of lung diseases, and controls.
[0379] 5.4.4 Use of compounds combining IL-13 and TSLP for the treatment of lung diseases
[0380] The present invention also provides the use of a compound combining IL-13 and TSLP for treating lung disease in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control.
[0381] In some embodiments, the present invention provides the use of a compound combining IL-13 and TSLP for treating a lung disease in a subject, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
[0382] All embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects (where the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control) can be transferred to the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control. This is particularly applicable to reductions in FeNO levels, time points, the nature of the compounds, the type of lung disease, and controls. For example, in some embodiments, the present invention provides the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 20 ppb, at least 30 ppb, or at least 40 ppb compared to a control.
[0383] The present invention also provides the use of a compound combining IL-13 and TSLP for treating a lung disease in a subject, wherein the treatment reduces the eosinophil count in the blood compared to a control.
[0384] In some embodiments, the present invention provides the use of a compound combining IL-13 and TSLP for treating a lung disease in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control.
[0385] All embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects (where the treatment reduces the eosinophil count in the blood compared to a control) can be transferred to the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects, where the treatment reduces the eosinophil count in the blood compared to a control. This is particularly applicable to the reduction in eosinophil count, time point, nature of the compound, type of lung disease, and control. For example, in some embodiments, the present invention provides the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects, where the treatment reduces the eosinophil count in the blood by at least 35% or at least 40% compared to a control.
[0386] This invention also provides the use of compounds combining IL-13 and TSLP for treating lung diseases in subjects, wherein the treatment reduces airway inflammation. All embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung diseases in subjects (wherein the treatment reduces airway inflammation) can be transferred to the use of compounds combining IL-13 and TSLP for treating lung diseases in subjects, wherein the treatment reduces airway inflammation. This is particularly applicable to the definition of airway inflammation reduction, time points, the nature of the compounds, the type of lung disease, and controls.
[0387] 5.4.5 Methods to reduce FeNO levels
[0388] The present invention also provides compounds for use in reducing FeNO levels in subjects and methods for reducing FeNO levels in subjects.
[0389] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing exhaled nitric oxide (FeNO) levels in a subject, wherein the compound reduces FeNO levels by at least 18 ppb compared to a control. The embodiments and examples given above for the compound combining IL-13 and TSLP for use in treating lung disease in a subject (where the treatment reduces exhaled nitric oxide (FeNO) levels compared to a control) can be transferred to the compound combining IL-13 and TSLP for use in reducing exhaled nitric oxide (FeNO) levels in a subject. This is particularly applicable to the reduction in FeNO levels, time points, the nature of the compound, and controls. For example, in some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing exhaled nitric oxide (FeNO) levels in a subject, wherein the compound reduces FeNO levels by at least 20 ppb, at least 30 ppb, or at least 40 ppb compared to a control.
[0390] In some embodiments, the present invention provides a method for reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein the compound reduces the FeNO level by at least 18 ppb compared to a control. The embodiments and examples given above for the use of compounds in combination with IL-13 and TSLP in treating lung disease in subjects (where the treatment reduces the level of exhaled nitric oxide (FeNO) compared to a control) can be transferred to a method for reducing the level of exhaled nitric oxide (FeNO) in a subject. This is particularly applicable to the reduction of FeNO levels, the time point, the nature of the compound, and the control. For example, in some embodiments, the present invention provides a method for reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein the compound reduces the FeNO level by at least 20 ppb, at least 30 ppb, or at least 40 ppb compared to a control.
[0391] 5.5 Preventive reduction of FeNO levels
[0392] On the other hand, the present invention relates to a preventative aspect. Because the present invention provides a way to reduce FeNO levels to a greater extent than known treatments, this opens up the possibility of prophylactic administration to subjects with elevated FeNO levels to prevent lung function loss even before it occurs. This prophylactic administration can be for asthmatic patients and subjects at risk of developing asthma, as well as patients with other lung diseases and subjects at risk of developing other lung diseases. Therefore, the present invention also provides compounds for use in reducing FeNO levels in subjects and methods for reducing FeNO levels in subjects, wherein the reduction of FeNO levels prevents lung function loss.
[0393] FeNO levels
[0394] The preventive reduction of FeNO levels according to the invention involves subjects who have elevated FeNO levels (hereinafter referred to as baseline FeNO levels) prior to the initiation of prophylactic administration. Elevated baseline FeNO levels are FeNO levels exceeding 25 ppb (see, for example, Miskoff et al., Cureus. 2019 June; 11(6):e4864).
[0395] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 90 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 80 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 75 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 70 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 65 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 60 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 55 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 45 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 40 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 30 ppb), wherein the reduction in FeNO levels prevents loss of lung function. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function.
[0396] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the subjects also have a FeNO level greater than or equal to 0.3 × 10⁻⁶. 9 Eosinophil count per cell / L, where a reduction in FeNO levels prevents loss of lung function.
[0397] FeNO reduction
[0398] In some embodiments, the reduction in FeNO level is a reduction of at least 18 ppb. In some embodiments, the reduction in FeNO level is a reduction of at least 20 ppb. In some embodiments, the reduction in FeNO level is a reduction of at least 25 ppb. In some embodiments, the reduction in FeNO level is a reduction of at least 30 ppb. In some embodiments, the reduction in FeNO level is a reduction of at least 35 ppb. In some embodiments, the reduction in FeNO level is a reduction to a normal level, which means a reduction to a level below 25 ppb.
[0399] FeNO level + FeNO reduction
[0400] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 25 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 20 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 18 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction to a level below 25 ppb.
[0401] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 25 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 20 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 18 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction to a level below 25 ppb.
[0402] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 25 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 20 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction of at least 18 ppb. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function and wherein the reduction in FeNO levels is a reduction to a level below 25 ppb.
[0403] Compounds used for the preventive reduction of FeNO levels
[0404] In some embodiments, the compound is a compound that binds to IL-13. Exemplary compounds that bind to IL-13 are the antibodies anrukinzumab, lejuchizumab, and trorocuzumab.
[0405] In some embodiments, the compound is a compound that binds to TSLP. An exemplary compound that binds to TSLP is the antibody terzrolumab.
[0406] In some embodiments, the compound is a compound that binds to IL-13 and TSLP. Exemplary compounds that bind to IL-13 and TSLP are given above (Section 5.3). In some embodiments, the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0407] FeNO level + FeNO reduction + compounds
[0408] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 25 ppb, and wherein said compound is a compound that binds to IL-13 and TSLP. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein... A reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 25 ppb, and wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or composed of the amino acid sequence of SEQ ID NO:1. In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 25 ppb, and wherein the compound is terzrolumab.
[0409] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, and wherein said compound is a compound that binds to IL-13 and TSLP. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein said reduction in FeNO levels is a reduction to a level below 25 ppb, and wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein said reduction in FeNO levels is a reduction to a level below 25 ppb, and wherein said compound is terzrolumab.
[0410] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 18 ppb, and wherein said compound is a compound that binds to IL-13 and TSLP. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 35 ppb), wherein... A reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 18 ppb, and wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or composed of the amino acid sequence of SEQ ID NO:1. In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 18 ppb, and wherein the compound is terzrolumab.
[0411] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, and wherein said compound is a compound that binds to IL-13 and TSLP. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein said reduction in FeNO levels is a reduction to a level below 25 ppb, and wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO level is at least 35 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein said reduction in FeNO levels is a reduction to a level below 25 ppb, and wherein said compound is terzrolumab.
[0412] In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction of at least 18 ppb, and wherein said compound is a compound that binds to IL-13 and TSLP. In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein said reduction in FeNO levels is a reduction of at least 18 ppb, and wherein said compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1. In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 25 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein said reduction in FeNO levels is a reduction of at least 18 ppb, and wherein said compound is terzrolumab.
[0413] Causes of lung function loss
[0414] Elevated FeNO levels are associated with a variety of lung diseases, including asthma and idiopathic pulmonary fibrosis (Cameli et al., Int J Mol Sci. 2020 Sep; 21(17):6187). Subjects with elevated baseline FeNO levels may already be exhibiting symptoms of asthma or are at risk of developing symptoms of another lung disease. These symptoms include loss of lung function. According to the present invention, this loss of lung function can be prevented by a preventative reduction in FeNO levels.
[0415] In some embodiments, the reduction of FeNO levels according to the invention prevents lung function loss associated with asthma. In some embodiments, the reduction of FeNO levels according to the invention prevents lung function loss associated with lung diseases other than asthma.
[0416] FeNO levels + FeNO reduction + compounds + causes of lung function loss
[0417] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, wherein the compound is a compound that binds to IL-13 and TSLP, and wherein the loss of lung function is associated with asthma. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1, and wherein the loss of lung function is associated with asthma. In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, wherein the compound is terzolumab, and wherein the loss of lung function is associated with asthma.
[0418] In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, wherein the compound is a compound that binds to IL-13 and TSLP, and wherein the loss of lung function is associated with a lung disease that is not asthma. In some embodiments, the present invention provides compounds for use in reducing FeNO levels in subjects (whose baseline FeNO levels are at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, wherein the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or composed of the amino acid sequence of SEQ ID NO:1, and wherein the loss of lung function is associated with a lung disease that is not asthma. In some embodiments, the present invention provides a compound for use in reducing FeNO levels in a subject (whose baseline FeNO level is at least 50 ppb), wherein the reduction in FeNO levels prevents loss of lung function, wherein the reduction in FeNO levels is a reduction to a level below 25 ppb, wherein the compound is terzolumab, and wherein the loss of lung function is associated with a lung disease that is not asthma.
[0419] The present invention also provides a method for reducing FeNO levels in a subject, wherein the reduction of FeNO levels prevents loss of lung function. All embodiments and examples given above for the use of compounds in reducing FeNO levels in a subject (where the reduction of FeNO levels prevents loss of lung function) can be transferred to the method for reducing FeNO levels in a subject, wherein the reduction of FeNO levels prevents loss of lung function.
[0420] The present invention also provides the use of the compound for preventing loss of lung function in a subject, wherein the compound reduces the subject's FeNO level. All embodiments and examples given above for use with the compound in reducing the subject's FeNO level (wherein the reduction of FeNO level prevents loss of lung function) can be transferred to the use of the compound for preventing loss of lung function in a subject, wherein the compound reduces the subject's FeNO level.
[0421] 5.6 Other aspects of the invention
[0422] 5.6.1 Treatment of small airway obstruction
[0423] The present invention also provides compounds for use in treating lung diseases in subjects, wherein the treatment reduces small airway obstruction. Therefore, the present invention provides the possibility of specifically treating patients with small airway obstruction (e.g., a subgroup of asthma patients with small airway obstruction).
[0424] Therefore, the present invention provides a compound combining IL-13 and TSLP for use in treating a lung disease in a subject, wherein the treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control, wherein the treatment reduces small airway obstruction. In some embodiments, the lung disease is asthma. In some embodiments, the control is a placebo. In some embodiments, the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1. In some embodiments, the lung disease is asthma and the control is a placebo. In some embodiments, the lung disease is asthma and the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1. In some embodiments, the control is a placebo and the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1. In some embodiments, the lung disease is asthma, the control is a placebo and the compound is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0425] 5.6.2 Decrease in eosinophil count
[0426] The present invention also provides compounds for use in reducing eosinophil counts in the blood of a subject and methods for reducing eosinophil counts in the blood of a subject.
[0427] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control. The embodiments and examples given above for the compound combining IL-13 and TSLP for use in treating lung disease in a subject (where the treatment reduces the eosinophil count in the blood by at least 30% compared to a control) can be transferred to the compound combining IL-13 and TSLP for use in reducing the eosinophil count in a subject. This is particularly applicable to the reduction in eosinophil count, the time point, the nature of the compound, and the control. For example, in some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 35% or at least 40% compared to a control.
[0428] In some embodiments, the present invention provides a method for reducing the eosinophil count in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control. The embodiments and examples given above for the use of compounds in combination with IL-13 and TSLP in treating lung disease in a subject (where the treatment reduces the eosinophil count in the blood compared to a control) can be transferred to a method for reducing the eosinophil count in a subject. This is particularly applicable to the reduction in eosinophil count, the time point, the nature of the compound, and the control. For example, in some embodiments, the present invention provides a method for reducing the eosinophil count in a subject, wherein the treatment reduces the eosinophil count in the blood by at least 35% or at least 40% compared to a control.
[0429] 5.6.3 Reduction in the proportion of non-classical monocytes
[0430] The present invention also provides compounds for use in reducing the proportion of non-classical mononuclear cells in the respiratory tract of a subject and methods for reducing the proportion of non-classical mononuclear cells in the respiratory tract of a subject.
[0431] Monocytes are a heterogeneous population of cells with the potential to become activated, infiltrate tissues from the bloodstream, and differentiate into macrophages. When activated, monocytes and macrophages release numerous inflammatory cytokines associated with the pathogenesis of asthma, and monocyte initiation and respiratory tissue infiltration in asthma have been described in numerous studies, indicating the important role of this cell type in the pathobiology of the disease (Li et al., Tomita et al.). Monocytes have been observed to rapidly accumulate in the nasal mucosa after local allergen provocation, where they promote the recruitment of Th2 cells and eosinophils. Recent analysis of bronchoalveolar lavage fluid using single-cell RNAseq has further identified several monocyte clusters, as well as an increased subset of monocyte-derived macrophages in patients with asthma exacerbations. Another recent study found monocyte accumulation in the lungs of children and adolescents with fatal asthma attacks (Eguíluz-Gracia et al., Clin Exp Allergy. 2018, December). The results strongly support the direct involvement of monocytes as pro-inflammatory cells in the immunopathology of asthma and suggest that SAR's prevention of them from entering respiratory tissues may have a beneficial effect in preventing asthma symptoms and exacerbations.
[0432] Therefore, a reduction in the proportion of monocyte subsets (e.g., non-classical monocytes) can be used in the treatment of asthma. This invention enables such a reduction, as illustrated in the following examples section.
[0433] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein said treatment reduces the proportion of non-classical monocytes in the subject's blood. The embodiments and examples given above for the compound combining IL-13 and TSLP for use in treating a subject's lung disease can be transferred to the compound combining IL-13 and TSLP for use in reducing the proportion of non-classical monocytes in a subject's blood. This is particularly relevant to the time point and the nature of the compound. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0434] In some embodiments, the present invention provides a method for reducing the proportion of non-classical monocytes in the blood of a subject. The embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung disease in a subject can be transferred to a method for reducing the proportion of non-classical monocytes in the blood of a subject. This is particularly applicable to time points and the nature of the compounds. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0435] 5.6.4 Decrease in the proportion of NK cells
[0436] The present invention also provides compounds for use in reducing the proportion of NK cells in the blood of a subject and methods for reducing the proportion of NK cells in the blood of a subject.
[0437] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein said treatment reduces the proportion of NK cells in the subject's blood. The embodiments and examples given above for the compound combining IL-13 and TSLP for use in treating a subject's lung disease can be transferred to the compound combining IL-13 and TSLP for use in reducing the proportion of NK cells in a subject's blood. This is particularly relevant to the time point and the nature of the compound. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0438] In some embodiments, the present invention provides a method for reducing the proportion of NK cells in the blood of a subject. The embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung disease in a subject can be transferred to a method for reducing the proportion of NK cells in the blood of a subject. This is particularly relevant to the time point and the nature of the compound. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0439] 5.6.5 Decreased CCL26 expression in endothelial cells
[0440] The present invention also provides compounds for use in reducing CCL26 expression in endothelial cells (such as basal epithelial cells, multiciliated epithelial cells, and secretory epithelial cells) of a subject, and methods for reducing CCL26 expression in endothelial cells (such as basal epithelial cells, multiciliated epithelial cells, and secretory epithelial cells) of a subject.
[0441] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein said treatment reduces CCL26 expression in the subject's endothelial cells. The embodiments and examples given above for the compound combining IL-13 and TSLP for use in treating lung disease in a subject can be transferred to the compound combining IL-13 and TSLP for use in reducing CCL26 expression in the subject's endothelial cells. This is particularly relevant to the time point and the nature of the compound. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0442] In some embodiments, the present invention provides a method for reducing CCL26 expression in the endothelial cells of a subject. This can be applied to the combination of IL-13 and... The embodiments and examples of the compounds for use in treating lung disease in subjects given by TSLP are transferred to methods for reducing CCL26 expression in the endothelial cells of subjects. This is particularly relevant to the time points and the nature of the compounds. For example, in some embodiments, the compound that combines IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0443] 5.6.6 Decreased HBB expression in T cells
[0444] The present invention also provides compounds for use in reducing HBB expression in T cells (such as CD8 T effector memory (em) cells) of a subject, and methods for reducing HBB expression in T cells (such as CD8 T effector memory (em) cells) of a subject.
[0445] In some embodiments, the present invention provides a compound combining IL-13 and TSLP for use in reducing the level of exhaled nitric oxide (FeNO) in a subject, wherein said treatment reduces HBB expression in the subject's T cells. The embodiments and examples given above for the compound combining IL-13 and TSLP for use in treating a subject's lung disease can be transferred to the compound combining IL-13 and TSLP for use in reducing HBB expression in a subject's T cells. This is particularly relevant to the time point and the nature of the compound. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0446] In some embodiments, the present invention provides a method for reducing HBB expression in T cells of a subject. The embodiments and examples given above for the use of compounds combining IL-13 and TSLP in treating lung disease in a subject can be transferred to a method for reducing HBB expression in T cells of a subject. This is particularly relevant to the time point and the nature of the compound. For example, in some embodiments, the compound combining IL-13 and TSLP is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or consisting of the amino acid sequence of SEQ ID NO:1.
[0447] 5.7 Practicality
[0448] The compounds used according to the invention can be used to treat subjects suffering from lung diseases such as asthma.
[0449] 6 Examples
[0450] 6.1 Example 1: PDY16622 - a three-center, double-blind, randomized, placebo-controlled, parallel design, single-dose asthma study.
[0451] Tested in the Phase I trial (PDY16622) detailed below. The efficacy of SAR443765 in treating asthma. The trial timeline is in... Figure 1 Described in the text.
[0452] 6.1.1 Method
[0453] patient groups
[0454] This study enrolled a total of 36 participants with mild to moderate asthma. Participants were randomized to either the SAR443765 group or the placebo group (24 SAR443765 and 12 placebo). Participants received a single dose at the highest safe and well-tolerated dose level (400 mg SC max), as assessed earlier in the study section with healthy adult participants.
[0455] Participants must meet the following criteria:
[0456] At the time of screening, candidates must have been diagnosed with asthma for at least 12 months and confirmed based on the Global Initiative for Asthma (GINA) 2020 guidelines, except for step 5 and step 4 with a high dose of inhaled corticosteroids (ICS).
[0457] Asthma is controlled as defined by an Asthma Control Questionnaire (ACQ)-5 score of <1.5.
[0458] The following participants were included: those using a short-acting beta-agonist (SABA) on demand, those who had not used ICS, or those with existing stable therapy (lasting at least 3 months prior to screening) including: low to moderate daily doses of ICS (≤500 mcg of fluticasone propionate or comparable total daily doses of ICS) (possibly in combination with a long-acting beta-agonist (LABA) and / or a long-acting muscarinic agonist (LAMA) as a second control agent), and / or stable daily leukotriene receptor antagonists, leukotriene synthesis inhibitors, and / or cromolyn.
[0459] Participants with elevated FeNO levels defined as ≥25 ppb at screening and baseline.
[0460] Participants whose pre-bronchodilator FEV1 was ≥60% of the expected normal value were screened.
[0461] During the screening period, reversibility of at least 12% and 200 mL in FEV1 or forced vital capacity (FVC) after four administrations (400 mcg) of abu-cetrol / salbutamol or levosalbutamol, or a history of reversibility testing that meets these criteria within 5 years prior to screening, or a positive response to methacholine provocation (20% reduction in FEV1 [PC20]: <8 mg / mL) within 5 years prior to the screening visit.
[0462] Normal or clinically acceptable vital signs (pulse rate, SBP, and DBP) after 10 minutes of rest in a supine position at screening and baseline.
[0463] Normal or clinically acceptable standard 12-lead electrocardiogram (ECG) parameters at screening and baseline, and the graph after 10 minutes of rest in the supine position; normal ECG graph, unless the investigator considers the ECG graph abnormality to be clinically relevant.
[0464] Laboratory parameters should be within the normal range (or the investigator's center-defined screening threshold) at screening and baseline, unless the investigator considers the abnormality to be clinically irrelevant; however, serum creatinine, alkaline phosphatase, and liver enzymes (aspartate aminotransferase, alanine aminotransferase) should not exceed 1.25 times the upper limit of laboratory guidelines. Total bilirubin exceeding the normal range is acceptable if it does not exceed 1.5 times the upper limit of normal conjugated bilirubin (unless the participant has a documented history of Gilbert's syndrome).
[0465] At screening and baseline, males should weigh between 50.0 kg and 105.0 kg (inclusive), and females should weigh between 40.0 kg and 95.0 kg (inclusive), with a body mass index (BMI) of 18.0 kg / m². 2 With 32.0 kg / m 2 Between (including end values).
[0466] Dosage
[0467] Participants were administered the drug in subgroups of up to four participants, at intervals of at least 10 minutes, with a dosing interval of at least 2 days between subgroups. The asthma cohort was initiated based on blinded safety and pharmacokinetic data from earlier study portions in healthy adult participants.
[0468] All participants were screened within 28 days to ensure they met study requirements. Eligible participants were admitted the day before each dose, and, taking into account emerging safety, PK, and PD data, participants included in the study remained institutionalized for one day after administration of the study drug in the asthma cohort. Prior to each drug administration, participants underwent assessment for SARS-CoV-2 infection and experienced intensive monitoring including physical examination, AE assessment, vital signs, ECG, and routine laboratory assessments (complete blood count and differential, chemistry, aPTT, PT-INR, high-sensitivity cardiac troponin T, and urinalysis). After one or more institutionalization periods, participants underwent clinical assessments at varying intervals, including vital signs, ECG, routine laboratory assessments, and ADA assessments, until the study was completed. Considering the half-life range of the nano-antibody that binds to serum albumin, the observation period for adverse events occurring during treatment in this study ended 70 days after the last dose.
[0469] Analysis of exhaled nitric oxide (FeNO) levels
[0470] In the research timeline ( Figure 1 Exhaled nitric oxide (FeNO) was measured at the time points specified in the study (i.e., baseline, D8, D15, D29, and D57). FeNO is a measure of NO production by epithelial cells in the lungs and is considered a biomarker of airway inflammation in asthma.
[0471] On-site use of specialized medical devices (such as commercially available handheld devices like NIOX) FeNO levels (ppb) will be collected. FeNO testing needs to be performed before the pulse oscillation method and spirometry to avoid any influence on nitric oxide measurement results. Given the diurnal variation of FeNO, assessment should be performed at approximately the same time of day (±2 hours) throughout the study. Participants should not eat within 1 hour prior to FeNO measurement, as this may affect the results. All carbonated beverages and nitrate-rich foods (e.g., vegetable juice, salads, lettuce, radishes, celery, broccoli, cauliflower, spinach, arugula, beets, parsley, leeks, cabbage, fennel, turnips, carrots, bacon, sausage, bacon) should be withheld for at least 2 hours before FeNO measurement. ICS (if any) should be discontinued for at least 4 hours before FeNO measurement. Participants should be seated during FeNO testing; however, standing is acceptable if the participant cannot sit. The participant's posture (sitting or standing) should remain constant throughout the study. Participants will inhale to total lung volume using a handheld device. Then exhale at 50 mL / s for 10 seconds (assisted by visual and auditory cues).
[0472] Eosinophil count
[0473] Using flow cytometry in the study timeline ( Figure 1 The eosinophil count in whole blood was determined at the time points specified in the protocol (i.e., at baseline and at D2 (24h), D4 (72h), D8 (1 week), D15 (2 weeks), D29 (4 weeks), D57 (8 weeks) and D71 (10 weeks)).
[0474] Spirometry results (FEV1 and FEF25-75)
[0475] In the research timeline ( Figure 1 FEV1 and FEF25-75 were determined by spirometry at the time points specified in the )
[0476] Spirometry should be performed according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) guidelines (2019 update). For the parameters being measured (including FEV1, peak expiratory flow (PEF), FVC, and forced expiratory flow (FEF) 25%–75%), spirometry should be performed after the bronchodilator washout period, based on the duration of its effect, as detailed in the ATS guidelines. For example, the bronchodilator discontinuation time is: at least 6 hours for SABA, at least 24 hours for LABA, and 36–48 hours for LAMA. Cromolyn needs to be discontinued at least 24 hours before spirometry. ICS, leukotriene receptor antagonists, and leukotriene synthesis inhibitors do not need to be discontinued before spirometry; however, ICS needs to be discontinued before FeNO assessment.
[0477] Spirometry is preferably performed in the morning at all visits, except in the afternoon in special circumstances where morning spirometry is not feasible. Throughout the study, spirometry should be performed at approximately the same time (±2 hours) at each visit. The same spirometer and standard spirometry technique (including calibration) should be used at all visits, and, where possible, the same person should perform the measurements. Three measurements meeting the ATS acceptability and repeatability criteria should be obtained at each visit.
[0478] Reversibility was determined by postbronchodilator spirometry. Reversibility was defined as the absolute increase in FEV1 and / or FVC after bronchodilator administration, and as measured by spirometry, as the percentage increase in postbronchodilator FEV1 or FVC relative to prebronchodilator FEV1 or FVC, respectively. After spirometry to measure prebronchodilator FEV1, participants received four spritzes of abuzotinol / salbutamol or levosalbutamol / levosalbutamol from a prepared metered-dose inhaler (MDI). Postbronchodilator spirometry should be performed after a waiting period of at least 10 minutes and may be repeated several times within approximately 30 minutes after bronchodilator administration.
[0479] Measurement results using the pulse oscillation method (R5-20 and AX)
[0480] In the research timeline ( Figure 1 The time points specified in the document are used to determine R5-20 and AX using the oscillation method.
[0481] Oscillatory testing is a complementary technique to spirometry, which is used to determine the mechanical properties of the lungs. While spirometry is the most commonly used technique for assessing airway function, it is not sensitive enough to evaluate small airways, becoming abnormal only in approximately 75% of small airway obstructions. Oscillatory testing is more sensitive in detecting small airway disease associated with poor disease control and type 2 inflammation. Therefore, oscillation testing allows for the assessment of the relative contributions of large and small airways in asthma. According to the ERS guidelines (Oostveen et al., EurRespir J. 2003; 22(6):1026-41), [the following guidelines are used]. The device (Thorasys, Montreal, Canada) performed the oscillation method during tidal breathing. According to the study protocol, the oscillation method was performed immediately before the spirometry method.
[0482] A multi-frequency signal ranging from 5 to 37 Hz superimposed oscillatory pressure and flow onto the participants' spontaneous breathing. Measurements were repeated for 20 seconds with intervals of approximately 20 seconds. Artifacts caused by coughing or glottal closure were removed by automatic software rejection. Quality control required at least three records with a coefficient of variation of ≤15% (Peters et al., Appl Physiol NutrMetab. 2016; 41(5):538-47). Only these data were used for data analysis.
[0483] Low frequencies (e.g., at 5 Hz) reach the small airways and reflect the total airways, while high frequencies (e.g., at 20 Hz) do not reach the small airways and therefore reflect only the central airways. Respiratory resistance (Rrs) reflects the energy required to propagate pressure waves through the airways and inflate the lung parenchyma. Total airway resistance is primarily determined by the central airways (80%) and to a lesser extent by the smaller airways (20%). Therefore, in a healthy state, Rrs have a low frequency dependence (Pride, Thorax. 1992; 47(4):317-20) and a low R5-20 (the difference between Rrs(R5) at 5 Hz and Rrs(R20) at 20 Hz). Central airway flow obstruction (a component of airflow limitation in asthma) increases Rrs at all frequencies (i.e., both R5 and R20 increase), and R5-20 is low (Làndsér et al., Chest. 1982; 81(5):586-91). In small airway diseases (also common in asthma), Rrs increase in a frequency-dependent manner at low frequencies (i.e., R5 increases more than R20). (Clément et al., Chest. 1983; 83(2):215-20). Therefore, the frequency dependence of Rrs (referred to as R5-20; the difference between Rrs at 5 Hz and Rrs at 20 Hz) reflects airway heterogeneity and increases with small airway obstruction (Otis et al., J Appl Physiol. 1956; 8(4):427-43).
[0484] Respiratory reactance (Xrs) is driven by the capacitive (recoil) characteristics of the respiratory system at low frequencies, where it reflects the soft tissue and lung parenchyma. However, at higher frequencies, Xrs is driven by the inertia of the moving column of air in the conduction airway. The resonant frequency (f...) res () is the point where the capacitance and inertial reactance are equal; in both obstructive and restrictive lung diseases, f res Both will increase (Pride, Thorax. 1992; 47(4): 317-20, Clément et al., Chest. 1983; 83(2): 215-20). AX is at 5Hz and f res The total respiratory reactance is a composite index of the total respiratory reactance across all frequencies between the area under the reactance curve (AUC) and has a unit of elastance, and is a measure of small airway disease and closure (as seen in asthma).
[0485] R5, R5-20, and AX are the most sensitive oscillatory indicators of small airway function (Goldman et al., Respir Physiol Neurobiol. 2005; 148(1-2):179-94; Oostveen et al., Eur Respir J. 2003; 22(6):1026-41; Oostveen et al., Eur Respir J. 2013; 42(6):1513-23). Therefore, AX, R5, and R5-20 are the focus of analysis for assessing treatment efficacy.
[0486] Transcriptome analysis
[0487] To enhance our understanding of the role of SAR443765 at the cellular level, single-cell RNA sequencing (scRNA-seq) was employed. This technology allows for the study of gene expression patterns at the individual cell level, enabling more detailed and comprehensive analysis. Through comparison... Gene expression patterns before and after SAR443765 treatment, as well as those of the SAR443765 treatment group compared to the placebo group, can identify specific cellular changes associated with SAR443765 treatment.
[0488] In this study, scRNAseq was performed on nasal brush (NB) and peripheral blood leukocyte (PBL) samples obtained from the SAR443765 group and the placebo group at D1 (before administration of SAR443765 or placebo) and D29.
[0489] scRNA-seq was performed as described in the literature (see, for example, Haque et al., Genome Med. 2017 Aug 18; 9(1):75 and Slovin et al., Methods Mol Biol. 2021; 2284:343-365). Nasal brush and PBL data were analyzed separately. The results of cell populations and gene expression from different samples were compared as a follow-up analysis to assess the consistency between samples.
[0490] SignacX v 2.2.4 was used to annotate cell types B. memory cells, B. immature cells, macrophages, classical monocytes, non-classical monocytes, neutrophils, eosinophils, NK cells, plasma, CD4.T. memory cells, CD4.T. immature cells, CD8.T.CM, CD8.T.EM, CD8.T. immature cells, Treg cells, fibroblasts, endothelial cells, and epithelial cell types (Chamberlain et al.). Because SignacX provides detailed algorithmic annotations for many immune cell types but only general classifications for non-immune cell types, Louvain clustering was run during Spring preprocessing, followed by marker gene expression analysis to annotate NB non-immune epithelial cell subtypes, dendritic cell subtypes (Villani et al.), and mast cells and eosinophils. Manual annotation of nasal epithelial cells based on cluster-level expression of previously published marker sets and marker gene sets (Deprez et al., Am J Respir Crit Care Med. December 15, 2020). June 15, 2022; 10:907511, Leggebeke et al., Front Cell Dev Biol., 2022; 202(12):1636-1645, Vieira Braga et al., Nat Med., July 2019; 25(7):1153-1163). Objects annotated in the SPRING pipeline were converted to common scRNAseq format data structures (Seurat and SingleCellExperiment objects), which were used as input to other single-cell data analysis packages for further analysis.
[0491] To summarize the results of preprocessing and annotation, clustering and cell type annotation (including the identification of new cell types and subtypes) were performed with dimensionality reduction of the normalized count data. The summary output shows the distribution of cell type abundance in terms of proportion and percentage, and reports the top marker genes for each cell type to confirm the allocation. These outputs are presented graphically.
[0492] Samples collected at baseline were analyzed to assess cell subsets and / or the presence of gene signatures potentially predicting FeNO reduction. Correlation analyses were performed using FeNO values at week 4 (D29) and / or changes in FeNO compared to baseline. Specifically, Spearman correlation analyses were performed on cell types that showed prominence in scRNASeq analysis regarding FeNO values at week 4 (D29) and / or changes in FeNO between D29 and D1 (baseline). Various correlation analyses were performed, such as between changes in cell type proportions compared to baseline and changes in FeNO, and between gene expression at baseline and changes in FeNO. Correlation values and p-values for these analyses are reported.
[0493] To gain further insight into the biological significance and asthma-related relevance of the data generated above, pathway analysis was used to study gene sets identified by differential expression analysis (D29 vs. D1). This pathway analysis was performed using integrated knowledge databases and available software such as Ingenuity Pathway Analysis (Qiagen) and Gene Set Enrichment Analysis (GSEA) (e.g., scGSEA). These tools allow for the identification of pathway initiation or inhibition through pathway module score analysis. Due to the relationship between specific gene lists and the biology of allergy and asthma and / or the TSLP / IL13 pathway, these specific gene lists were investigated, including but not limited to genes in the TSLP and IL-13 pathways (e.g., IL-4, IL-13, IFNa, IFNg) (Giovannini-Chami et al., Eur Respir J. 2012; 39(5):1197-205, Kramer et al., Bioinformatics. 2014; 30(4):523-30, Adhikary et al., Pharmacol Ther. 2021; 217:107648).
[0494] 6.1.2 Results
[0495] exist Figure 1 The following data were collected at the indicated time points: FeNO levels ( Figure 2 and Figure 3 ); Eosinophil count in the blood ( Figure 4 and Figure 5 ), FEV1 ( Figure 6 , Figure 7 , Figure 8 ), FEF25-75 Figure 9 R5-20 Figure 10 ), AX( Figure 11 Other biomarkers in serum / plasma ( Figure 12 Transcriptome analysis Figure 13, Figure 14 , Figure 15 , Figure 16 ).
[0496] FeNO levels
[0497] Figure 2 The table shows the change in FeNO levels from baseline in participants treated with SAR443765 (dashed line) or placebo (solid line). The dose of SAR443765 was 400 mg, and FeNO levels were measured at one week (D8), two weeks (D15), four weeks (D29), and eight weeks (D57) after administration of SAR443765 or placebo. Table 1 shows the results of those FeNO level measurements. The baseline value was defined as the last available value before and closest to the first dose of the investigational drug. Compared with placebo, SAR443765 treatment was found to reduce FeNO levels by 31.1 ppb (-31.9 ppb - 0.8 ppb) at one week (D8), 54.0 ppb (-35.2 ppb - 18.8 ppb) at two weeks (D15), 39.9 ppb (-39.1 ppb - 0.8 ppb) at four weeks (D29), and 35.9 ppb (-32.0 ppb - 3.9 ppb) at eight weeks (D57).
[0498] In the SAR443765 group, 37% of participants had normal FeNO levels (below 25 ppb) at the end of the study, compared to only 8% in the placebo group.
[0499] Table 1: Changes in FeNO levels after SAR443765 treatment. All FeNO levels are indicated in ppb.
[0500] Table 2 shows baseline FeNO values and reductions after 4 weeks (D29) of this study, as well as several published results regarding other biologics, including terzerulimab (anti-TSLP), lerechizumab (anti-IL-13), trorocuzumab (anti-IL-13), benazelimab (anti-IL-5Ra), dupilumab (anti-IL-4Ra), and etanerpe (anti-IL-33). SAR443765 showed a stronger reduction in FeNO levels than all other compounds, with a reduction more than 2-fold higher than the highest reduction achieved in a study using another compound (18 ppb in the lerechizumab study). This study demonstrates that administration of a compound that blocks both IL-13 and TSLP significantly increases FeNO reduction by approximately 2 to 4-fold compared to single-specific approaches.
[0501] Table 2: Comparison of FeNO reduction by SAR443765 and other biologics used for asthma treatment. All FeNO levels are indicated in ppb.
[0502] Subgroup analysis
[0503] Figure 3 The results showed that the eosinophil count was separated from the baseline eosinophil count of the participants. Figure 2 The same measurements were used. The following group was characterized by high baseline eosinophil counts (≥0.3 × 10⁻⁶). 9 SAR443765 (dashed line) at the condition of cells / L, low baseline eosinophil count (<0.3×10⁻⁶ cells / L), indicating a low baseline eosinophil count. 9 SAR443765 (solid line below) at the condition of cells / L, high baseline eosinophil count (≥0.3*10⁻⁶ cells / L), and high baseline eosinophil count (≥0.3*10⁻⁶ cells / L). 9 Placebo (upper dashed line) at a baseline eosinophil count of <0.3 × 10⁻⁶ cells / L, low baseline eosinophil count (<0.3 × 10⁻⁶ cells / L). 9 The placebo group (top solid line) at 1 cell / L. Results for these four groups at D29 (4 weeks) are also depicted in Table 3.
[0504] Table 3: Changes in FeNO levels after SAR443765 treatment in the high and low eosinophil subgroups. All FeNO levels are indicated in ppb.
[0505] The treatment of this invention resulted in a significant reduction in FeNO levels in both groups. For participants with high eosinophil counts, the reduction was 53.0 ppb (64.34% of baseline) compared to placebo, and for participants with low eosinophil counts, the reduction was 33.5 ppb (47.58% of baseline) compared to placebo. This indicates that the treatment of this invention resulted in a similar relative reduction in FeNO in both participant groups, exceeding the FeNO reductions seen with any other biologic (see Table 2).
[0506] Eosinophil count
[0507] Figure 4The changes in eosinophil counts in participants treated with SAR443765 (right column) or placebo (left column) at D29 (4 weeks) are shown. SAR443765 treatment resulted in a median change of -42.42% in eosinophil count, while the placebo group showed a median change of -0.38% in eosinophil count. This demonstrates that SAR443765 causes a strong reduction in eosinophil count compared to placebo. Figure 5 The changes in eosinophil counts on D29 are shown for SAR443765 and other biologics (lerechizumab, terzolumab, and dupilumab). SAR443765 showed a decrease of the same range as terzolumab. Note that dupilumab (which blocks IL-13 signaling like SAR443765) showed an increase in eosinophil count here. This increase in eosinophils was not observed with SAR443765.
[0508] Table 4 shows the results of eosinophil counts on days 2, 4, 8, 15, 29, 57, and 71 after SAR443765 treatment.
[0509] Table 4: Changes in eosinophil count after SAR443765 treatment. All eosinophil counts were set at 10-1. 9 Cells / L indicator.
[0510] FEV1
[0511] FEV1 (forced expiratory volume in one second) is the maximum volume of air that can be exhaled in the first second of exhalation, starting from maximal inspiration. In this study, FEV1 was determined using the spirometry method described above. Figure 6 The changes in FEV1 (compared to baseline) are shown in participants who were treated with SAR443765 (dashed line) or placebo (solid line). The dose of SAR443765 was 400 mg. Figure 6 All available FEV1 measurements are depicted. Figure 7 The same measurement results are displayed, but excluding values where the measurement results do not meet all quality standards, which are defined as a difference between the two largest FEV1 values in triplicate > 0.150L. From Figure 6 The results showed that, compared with placebo, the treatment of this invention resulted in an increase of approximately 0.25 L in FEV1 after one week (D8), approximately 0.2 L after two weeks (D15), and approximately 0.07 L after four weeks (D29) and eight weeks (D57). Figure 7The results were similar for D8 and D29, but showed a smaller difference for D15 and no significant difference for D57. These results suggest that SAR443765 improves FEV1. However, further studies with larger patient cohorts and more impaired baseline FEV1 are needed to confirm this finding.
[0512] To gain a deeper understanding of the different patient subgroups, FEV1 improvement was analyzed in subgroups with normal and impaired lung function at baseline. Participants were categorized into one of these groups based on their baseline FEV1 percentage of predicted value (i.e., before starting treatment with SAR443765 or placebo). FEV1 percentage of predicted value (abbreviated as "ppFEV1") is the ratio (in percentages) between a participant's actual FEV1 and a reference FEV1, reflecting the mean for individuals with participant demographic characteristics such as age, sex, and body composition. Participants with a baseline ppFEV1 ≥ 80% were categorized into the normal baseline lung function subgroup, while those with a baseline ppFEV1 < 80% were categorized into the impaired baseline lung function subgroup. Therefore, data from both the SAR443765 and placebo groups were divided into two subgroups based on this criterion. The FEV1 results for these four subgroups are shown below. Figure 8 The results show that... Figure 7 The overall improvement in FEV1 observed (especially on days 8, 15, and 29 after SAR443765 treatment) was primarily due to improvements in the subgroup with impaired baseline lung function (ppFEV1 < 80%), while the subgroup with normal baseline lung function (ppFEV1 ≥ 80%) showed almost no improvement, possibly due to a ceiling effect.
[0513] FEF25-75
[0514] FEF25-75 (forced expiratory flow rate 25%-75%) refers to a portion of FVC (forced vital capacity), which is the maximum volume of air a patient can exhale after a maximal inspiration. FEF25-75 is the fraction of the exhaled FVC over the time span between 25% and 75% of the exhaled FVC, divided by the time taken to exhale that volume. Impairment of FEF25-75 can indicate small airway obstruction. In this study, FEF25-75 was determined using the spirometry method described above.
[0515] Figure 9 The image shows FEF25-75 data for the entire patient population (top) and subgroups with normal baseline lung function (ppFEV1 ≥ 80%) and impaired baseline lung function (ppFEV1 < 80%) (bottom). Figure 8The results are explained by the FEV1 results. SAR443765 improved FEV25-75 across the entire patient population (left panel), particularly on days 8 and 15. Subgroup results (right panel) indicate that this overall improvement in FEV25-75 seen in the left panel is primarily due to the SAR443765 subgroup with impaired baseline lung function (ppFEV1 < 80%), which showed an improvement of approximately 0.4–0.5 L / s, while the subgroup with normal baseline lung function (ppFEV1 ≥ 80%) showed almost no improvement compared to baseline. These results provide evidence that SAR443765 treatment reduces small airway obstruction in asthmatic patients.
[0516] R5-20
[0517] As noted above, R5-20 is the difference between respiratory resistance at 5 Hz and respiratory resistance at 20 Hz. Resistance at 5 Hz indicates resistance throughout the respiratory system (small and large airways), while resistance at 20 Hz indicates resistance within the large airways. Therefore, an elevated R5-20 indicates increased resistance (and thus obstruction) in the small airways. R5-20 is determined using the pulse oscillation method as described above.
[0518] Figure 10 The chart shows the R5-20 values for the entire patient population (top) and subgroups with normal baseline lung function (ppFEV1 ≥ 80%) and impaired baseline lung function (ppFEV1 < 80%) (bottom), as shown above. Figure 8 The results were explained by FEV1. R5-20 decreased across the entire patient population, exceeding the value of 0.31 cmH2O*s / L (0.03 kPa*s / L), which is considered a clinically significant threshold (Foy B et al., Am J Respir Crit Care. 2019; 200(8):982-991). The effects were most pronounced at D8 and D15. While SAR443765 had little effect in the normal baseline lung function (ppFEV1 ≥ 80%) subgroup, R5-20 was significantly reduced in the impaired baseline lung function (ppFEV1 < 80%) subgroup. This suggests that SAR443765 treatment alleviates small airway obstruction, particularly in asthmatic patients with impaired lung function.
[0519] As noted above, the reactance area (AX) is calculated based on lung reactance measurements (see also Desiraju and Agrawal, 2016). It includes the total area dominated by capacitance and reflects the capacitive (recoil) characteristics of the lung. From reactance and f res It can be seen that AX increases in any peripulmonary disease. AX is determined using the pulse oscillation method described above.
[0520] Figure 11 The image shows AX of the entire patient population (top) and subgroups with normal baseline lung function (ppFEV1 ≥ 80%) and impaired baseline lung function (ppFEV1 < 80%) (bottom), as shown above. Figure 8 The FEV1 results were explained. SAR443765 reduced AX in the entire patient population, exceeding a value of 6.65 cmH2O / L (0.65 kPa / L), which is considered a clinically significant threshold (Abdo et al., Eur Respir J. 2023; 61(5):2201793). The effect was most pronounced at D8 and D15. Although there was little effect in the normal baseline lung function (ppFEV1 ≥ 80%) subgroup, SAR443765 administration resulted in a significant reduction in the impaired baseline lung function (ppFEV1 < 80%) subgroup. This suggests that SAR443765 treatment alleviates small airway obstruction, especially in asthmatic patients with impaired lung function.
[0521] Other biomarkers
[0522] In addition to the parameters shown above, the following biomarkers were determined in the above clinical trials using SAR443765: serum IL-5 levels; plasma CCL26 (eosinophil chemokine-3) levels; serum TARC (CCL17) levels; and serum IgE levels. The levels of these biomarkers were determined according to methods generally known in the art. The results of D29 are shown in... Figure 12 Treatment with SAR443765 resulted in a reduction of all observed biomarkers compared to baseline.
[0523] Transcriptome analysis
[0524] Transcriptome analysis was performed using single-cell RNA sequencing (scRNAseq). scRNAseq was used to determine gene expression at the single-cell level in nasal brush (NB) and peripheral blood leukocyte (PBL) samples. Samples were obtained on D1 (baseline, before administration of SAR443765 or placebo) and D29. Analysis of gene expression allowed for the identification of cell types and their proportions. Figure 13 , Figure 14 The correlation between changes in this ratio and changes in FeNO levels ( Figure 15 ), and analyze the expression of individual genes for each cell type ( Figure 16 ).
[0525] Figure 13The different cell types found in the nasal brush samples were depicted. The change in the proportion of each cell type on the x-axis (D29 vs. D1) (expressed as log2 of the fold change (FC)) was plotted against the p-value of that change on the y-axis (expressed as -log10 of the p-value). In this analysis, a p-value ≤ 0.05 (corresponding to a value of at least around 1.3 on the y-axis) was considered significant. Decreased (“downregulated”) cell types were marked with triangles, unchanged cell types with dots, and increased (“upregulated”) cell types with squares. A significant decrease in the proportion of non-classical monocytes was found in the SAR443765 group, while no significant change was found in the placebo group. Since nasal brush samples can be considered an indicator of the entire airway, this is a first indication that the proportion of non-classical monocytes in the lung airways may also be reduced. The reduction in airway inflammation induced by SAR443765 may include a reduction in the proportion of non-classical monocytes in the airways.
[0526] There were no significant changes in other identified immune cell types in the SAR443765 group or the placebo group.
[0527] Figure 14 Different cell types found in peripheral blood leukocyte (PBL) samples were depicted. The change in the proportion of each cell type on the x-axis (D29 vs. D1) (expressed as log2 of the fold change (FC)) was plotted against the p-value of that change on the y-axis (expressed as -log10 of the p-value). In this analysis, a p-value ≤ 0.05 (corresponding to at least 1.3 on the y-axis) was considered significant. Significantly reduced proportions of NK cells and CD8 T effector memory (em) cells were found in the SAR443765 group. A significantly increased proportion of neutrophils was observed, while other measurements showed no increase in the total number of neutrophils. This is evidence of rebalancing the immune system by alleviating type 2 inflammation and thus reducing the number of cells associated with type 2 inflammation. No significant changes were observed in the placebo group. This suggests... The anti-inflammatory effects of SAR443765 may include a reduction in the proportion of NK cells and CD8 T em cells.
[0528] There were no significant changes in other identified immune cell types in the SAR443765 group or the placebo group.
[0529] Figure 15 The correlation between changes in FeNO levels (D29 vs. D1) and changes in the proportion of NK cells in the PBL samples (D29 vs. D1) was plotted. The Y-axis shows changes in the proportion of NK cells (log10 fold change in NK cells (FC)), while the x-axis shows changes in FeNO levels (in bbp). Each point indicates the value for one participant. The left plot shows the SAR443675 group and the placebo group, while the right plot shows only the placebo group. The SAR443765 group. Clearly, compared to the combination of the SAR443765 group and the placebo group, the correlation between changes in FeNO levels and changes in NK cell proportions was much stronger in the SAR443765 group alone. This suggests a possible link between SAR443765-induced FeNO reduction and a decrease in the proportion of NK cells in the blood, which may be part of the therapeutic effect of SAR443765.
[0530] Figure 16 The changes in CCL26 gene expression in different cell types in the nasal brush sample are shown (D29 vs. D1). For each cell type, there are two bars, the left corresponding to D1 and the right to D29. Although CCL26 expression was not significantly reduced in the placebo group (top panel), its expression was significantly reduced in basal epithelial cells, multiciliated epithelial cells, and secretory epithelial cells after SAR443765 treatment (bottom panel). The results for multiciliated epithelial cells are again shown magnified in the upper right corner of the figure. These results confirm the discovery of CCL26 / eosinophil chemokine-3 at the protein level (see [link to figure]). Figure 12 ).
[0531] As shown above (see Figure 14 SAR443765 treatment reduced the proportion of CD8 T effector memory (em) cells in PBL samples. Furthermore, SAR443765 caused a significant (adjusted p-value < 0.05) downregulation of the HBB gene encoding β-globin in CD8 T em cells. Figure 17 High HBB expression is described as being associated with low FEV1 in asthma. Therefore, a reduction in HBB expression may be an indicator of successful treatment.
[0532] Pathway Analysis
[0533] As noted above, in the PBL samples, the proportion of neutrophils in the SAR443765 group was significantly increased, while other measurements showed no increase in the total number of neutrophils. Figure 14To investigate the initiation state of neutrophils, gene expression data from scRNAseq underwent pathway analysis. Lists of genes for specific pathways were known from the literature (Giovannini-Chami et al., Kramer et al., Adhikary et al.) and could be grouped into so-called “pathway modules.” Pathway modules for IL-4, IL-13, interferon α (IFNa), and interferon γ (IFNg) were identified. Each pathway module was assigned a score at each time point (D1 and D29) corresponding to the expression of the gene in that module. The difference in pathway module scores from D29 and D1 (Δscore) indicated whether the respective pathway was upregulated or downregulated. Table 5 shows those score differences between SAR443765 and placebo.
[0534] Table 5: Pathway module scores of neutrophils in PBL samples. A p-value below 0.05 indicates significance.
[0535] For SAR443765, negative score differences were observed in the pathway modules of Il-4, IFNa, and IFNg, indicating reduced activity of these pathways in peripheral blood neutrophils. Since this reduction was not observed in placebo, the effect can be attributed to SAR443765.
[0536] References
[0537] Abdiche et al.Anal Biochem.2008 Jun 15;377(2):209-17
[0538] Abdo et al.,2023Eur Respir J.2023 May 5;61(5):2201793
[0539] Adhikary et al.,Pharmacol Ther.2021;217:107648
[0540] American Thoracic Society(ATS) / European Respiratory Society(ERS)Guidelines,2019 update:Graham et al.,Am J Respir Crit Care Med.2019 Oct 15;200(8):e70-e88
[0541] Cameli et al.,Int J Mol Sci.2020 Sep;21(17):6187
[0542] Castro et al., Lancet Respir Med.2014 Nov;2(11):879-890
[0543] Chamberlain et al., Fortune Journals 2023;6(3),152-177
[0544] Clément et al., Chest. 1983; 83(2):215-20
[0545] Conrath et al.,J Biol Chem.2001 Mar 9;276(10):7346-50
[0546] Corren et al.,N Engl J Med.2011 Sep 22;365(12):1088-98
[0547] Corren et al.,N Engl J Med.2017 Sep 7;377(10):936-946
[0548] Davies and Riechmann,Protein Eng.1996 Jun;9(6):531-7
[0549] Deprez et al.Am J Respir Crit Care Med.2020 Dec 15;202(12):1636-1645
[0550] Desiraju and Agrawal,Lung India.2016 Jul-Aug;33(4):410–416.
[0551] Drake et al.,Anal Biochem.2004 May 1;328(1):35-43
[0552] Eguíluz-Gracia et al.,Clin Exp Allergy.2018 Dec;48(12):1631-1639
[0553] Foy B,et al.Am J Respir Crit Care.2019;200(8):982–991
[0554] Fraley et al.,Bioanalysis.2013 Jul;5(14):1765-74
[0555] Gauvreau et al.,N Engl J Med.2014 May 29;370(22):2102-10
[0556] Gieseck III et al.,Nat Rev Immunol.2018 Jan;18(1):62-76
[0557] Giovannini-Chami et al.,Eur Respir J.2012;39(5):1197-205
[0558] Global Initiative for Asthma 2020 Guidelines:Global strategy forasthma management and prevention,2020[cited 2021 May 07].Available from:URL:www.ginasthma.org.
[0559] Goldman et al.,Respir Physiol Neurobiol.2005;148(1-2):179-94
[0560] Hamers-Casterman et al.,Nature.1993 Jun 3;363(6428):446-8
[0561] Haque et al.,Genome Med.2017 Aug 18;9(1):75
[0562] Johnnson et al.Anal Biochem.1991 Nov 1;198(2):268-77
[0563] Johnsson et al.,J Mol Recognit.1995 Jan-Apr;8(1-2):125-31
[0564] et al., Ann Biol Clin (Paris). 1993; 51(1):19-26
[0565] et al., Biotechniques. 1991 Nov; 11(5):620-7.
[0566] Korenblat et al.,Respir Med.2018 Jan;134:143-149
[0567] Kramer et al.,Bioinformatics.2014;30(4):523-30
[0568] Làndsér et al., Chest. 1982; 81(5):586-91
[0569] Legebeke et al.,Front Cell Dev Biol.2022 Jun 15;10:907511
[0570] Li et al.,J Allergy Clin Immunol.2021 Mar;147(3):941-954
[0571] McNulty and Usmani,Eur Clin Respir J,2014;1:10.3402 / ecrj.v1.25898
[0572] Menzies-Gow et al.,N Engl J Med.2021 May 13;384(19):1800-1809
[0573] Miskoff et al.,Cureus.2019 Jun;11(6):e4864
[0574] Muyldermans,J Biotechnol.2001 Jun;74(4):277-302
[0575] Ober et al.,Int Immunol.2001 Dec;13(12):1551-9
[0576] Oostveen E,et al.Eur Respir J.2013;42(6):1513-23
[0577] Oostveen et al., Eur Respir J.2003;22(6):1026-41
[0578] Ordovas-Montanes et al., Nature. 2018; 560(7720):649-54.
[0579] Otis et al.,J Appl Physiol.1956;8(4):427-43
[0580] Panettieri et al., Immunotherapy.2018 Mar 1;10(6):473-490
[0581] Panettieri et al., Lancet Respir Med.2018 Jul;6(7):511-525
[0582] Peters et al.,Appl Physiol Nutr Metab.2016;41(5):538-47
[0583] Pride,Thorax.1992;47(4):317-20
[0584] Russell et al., Lancet Respir Med.2018 Jul;6(7):499-510
[0585] Slovin et al.,Methods Mol Biol.2021;2284:343-365
[0586] Stockley et al., Int J Chron Obstruct Pulmon Dis. 2017; 12:2343–2353
[0587] Tomita et al.,J Allergy Clin Immunol.1995 Aug;96(2):230-8
[0588] Venkataramani et al.,Biochem Biophys Res Commun.2018 Sep 26;504(1):19-24
[0589] Vieira Braga et al.,Nat Med.2019 Jul;25(7):1153-1163
[0590] Villani et al.,Science.2017 Apr 21;356(6335)
[0591] Wechsler et al.,Lancet Respir Med.2022 Jul;10(7):650-660
[0592] Wechsler et al.,N Engl J Med.2021 Oct 28;385(18):1656-1668
[0593] Wenzel et al.,Lancet.2016 Jul 2;388(10039):31-44
[0594] WO 94 / 04678-IMMUNOGLOBULINS DEVOID OF LIGHT CHAINS
[0595] WO 96 / 34103-VARIABLE FRAGMENTS OF IMMUNOGLOBULINS-USE FOR THERAPEUTICOR VETERINARY PURPOSES
[0596] WO 99 / 23221-MULTIVALENT ANTIGEN-BINDING PROTEINS
[0597] WO 2021116182-POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLEDOMAINS TARGETING IL-13 AND TSLP
[0598] Ziegler&Artis,Nat Rev Immunol(2010)11:289-93
Claims
1. A compound combining IL-13 and TSLP, the use of said compound in treating a lung disease in a subject, wherein said treatment reduces the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
2. The compound for the stated use according to claim 1, wherein the treatment reduces the level of FeNO by at least 20 ppb, at least 30 ppb, or at least 40 ppb compared to a control.
3. The compound for the use according to any one of the preceding claims, wherein the lung disease is asthma.
4. The compound for the use according to claim 3, wherein the asthma is hypereosinophilic asthma.
5. The compound for the use according to claim 3, wherein the asthma is hypoeosinophilic asthma.
6. The compound for the use according to any one of the preceding claims, wherein the control is a baseline or wherein the control is a placebo, optionally wherein the baseline refers to the individual baseline of the subject.
7. The compound for the use according to any one of the preceding claims, wherein the reduction in FeNO level occurs within 4 weeks after application of the compound, wherein optionally the reduction in FeNO level occurs within 2 weeks after application of the compound, and wherein optionally the reduction in FeNO level occurs within 1 week after application of the compound.
8. A compound for the purpose according to any one of the preceding claims, wherein the compound binding IL-13 and TSLP is a polypeptide, such as an antibody or antibody fragment.
9. The compound for the purpose according to claim 8, wherein the polypeptide comprises or consists of at least four ISVDs, wherein two ISVDs specifically bind to IL-13 and two ISVDs specifically bind to TSLP, wherein each of the at least four ISVDs comprises three complementarity-determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptide linkers, and wherein: The first ISVD includes: CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:7, CDR2 is the amino acid sequence of SEQ ID NO:12, and CDR3 is the amino acid sequence of SEQ ID NO:17; The second ISVD includes: CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:8, CDR2 is the amino acid sequence of SEQ ID NO:13, and CDR3 is the amino acid sequence of SEQ ID NO:18; The third ISVD includes: CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:9, CDR2 is the amino acid sequence of SEQ ID NO:14, and CDR3 is the amino acid sequence of SEQ ID NO:
19. The fourth ISVD includes: CDR1, CDR2, and CDR3, wherein CDR1 is the amino acid sequence of SEQ ID NO:11, CDR2 is the amino acid sequence of SEQ ID NO:16, and CDR3 is the amino acid sequence of SEQ ID NO:
21.
10. The compound for the purpose according to claim 8 or 9, wherein the polypeptide comprises or is composed of the amino acid sequence of SEQ ID NO:
1.
11. The compound for the use according to any one of the preceding claims, wherein the subject has a baseline FeNO level of at least 50 ppb and an eosinophil count greater than or equal to 0.3 × 10⁻⁶. 9 Cells / L 12. The use of a compound combining IL-13 and TSLP in treating a subject with a lung disease, wherein the treatment reduces the eosinophil count in the blood by at least 30% compared to a control.
13. The compound for the stated use according to claim 12, wherein the reduction in eosinophil count occurs within 4 weeks after application of the compound, wherein optionally the reduction in eosinophil count occurs within 2 weeks after application of the compound, and wherein optionally the reduction in eosinophil count occurs within 1 week after application of the compound.
14. The use of a compound combining IL-13 and TSLP in treating a lung disease in a subject, wherein the treatment reduces airway inflammation.
15. The compound for the said use according to claim 14, wherein the reduction of airway inflammation is characterized by a reduction of at least 18 ppb in FeNO, a reduction of at least 30% in eosinophil count, and / or an increase of at least 0.07 L in forced expiratory volume in one second (FEV1) compared to a control.
16. The compound for the stated use according to claim 15, wherein the reduction of airway inflammation occurs within 4 weeks after administration of the compound, wherein optionally the reduction of airway inflammation occurs within 2 weeks after administration of the compound, and wherein optionally the reduction of airway inflammation occurs within 1 week after administration of the compound.
17. A compound that combines TSLP and / or IL-13, the use of said compound in reducing FeNO levels in a subject, wherein said reduction in FeNO levels prevents loss of lung function.
18. The compound for the said use according to claim 17, wherein the reduction in FeNO level is a reduction of at least 18 ppb.
19. The compound for the said use according to claim 17 or 18, wherein the reduction in FeNO level is a reduction to a level below 25 ppb.
20. The compound for the use according to any one of claims 17-19, wherein the baseline FeNO level of the subject is at least 50 ppb, at least 35 ppb, or at least 25 ppb.
21. The compound for the purpose according to any one of claims 17-20, wherein the subject's baseline FeNO level is at least 50 ppb and the eosinophil count is greater than or equal to 0.3 × 10⁻⁶. 9 Cells / L 22. The compound for the purpose according to any one of claims 17-21, wherein the compound is in combination with TSLP and IL-13.
23. The compound for the use according to any one of claims 17-21, wherein the loss of lung function is associated with asthma.
Citation Information
Patent Citations
Immunoglobulins devoid of light chains
WO1994004678A1
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1996034103A1
Multivalent antigen-binding proteins
WO1999023221A2
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
WO2021116182A1
